[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 14441
1. Chen XL, Ma Y, Wan Y, Duan LG: Experimental study of the safety of pancreas cryosurgery: the comparison of 2 different techniques of cryosurgery. Pancreas; 2010 Jan;39(1):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experimental study of the safety of pancreas cryosurgery: the comparison of 2 different techniques of cryosurgery.
  • OBJECTIVES: To test the feasibility of cryosurgery for pancreatic carcinoma and to observe the consequence of cryosurgery by 2 different techniques.
  • METHODS: Twelve healthy pigs underwent laparotomy, during which, chop amputation of common bile duct and duodenum were performed, meanwhile other intra-abdominal organs with the pancreas were isolated.
  • Two different techniques of cryosurgery were performed on the pancreas.
  • All animals in group B survived during the observation, in which only a transient increment and a gradual correction of pancreatic amylase level were recorded.
  • Small pancreatic pseudocyst occurred in 1 case.
  • CONCLUSIONS: Mild hypothermic cryosurgery with liquid nitrogen superficial refrigeration might lead to pancreatic injury and induce acute pancreatitis, yet deep hypothermic cryosurgery with adequate time showed a promising effect in destroying pancreatic tissue and preventing acute pancreatitis.
  • [MeSH-major] Cryosurgery / methods. Pancreas / surgery

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952969.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Ryan GA, Wang CJ, Chamberlain JL, Attridge K, Schmidt EM, Kenefeck R, Clough LE, Dunussi-Joannopoulos K, Toellner KM, Walker LS: B1 cells promote pancreas infiltration by autoreactive T cells. J Immunol; 2010 Sep 01;185(5):2800-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B1 cells promote pancreas infiltration by autoreactive T cells.
  • The entry of autoreactive T cells into the pancreas is a critical checkpoint in the development of autoimmune diabetes.
  • In transgenic mice with islet-specific T cells, but no B cells, T cells are primed in the pancreatic lymph node but fail to enter the pancreas.
  • Reconstitution of the B1 cell population by adoptive transfer permits extensive T cell pancreas infiltration.
  • Reconstituted B1 cells traffic to the pancreas and modify expression of adhesion molecules on pancreatic vasculature, notably VCAM-1.
  • Despite substantial pancreas infiltration, islet destruction is minimal unless regulatory T cells are depleted.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2007 Jan;170(1):240-50 [17200197.001]
  • [Cites] J Exp Med. 2006 Oct 30;203(11):2541-50 [17060475.001]
  • [Cites] Immunity. 2007 Jul;27(1):35-48 [17600736.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3857-67 [18060033.001]
  • [Cites] Diabetes. 2008 Apr;57(4):909-17 [18184927.001]
  • [Cites] J Immunol. 2008 Apr 15;180(8):5393-401 [18390721.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1701-6 [10677521.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2841-9 [10946317.001]
  • [Cites] Diabetes. 2001 Apr;50(4):763-70 [11289040.001]
  • [Cites] N Engl J Med. 2001 Oct 4;345(14):1036-40 [11586956.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4351-7 [11591759.001]
  • [Cites] Immunity. 2002 Feb;16(2):219-30 [11869683.001]
  • [Cites] Nat Rev Immunol. 2002 Jan;2(1):11-9 [11908514.001]
  • [Cites] Nat Immunol. 2002 Oct;3(10):944-50 [12244307.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6202-9 [12444125.001]
  • [Cites] J Immunol. 2002 Dec 1;169(11):6617-24 [12444175.001]
  • [Cites] J Exp Med. 2003 Jul 21;198(2):249-58 [12874258.001]
  • [Cites] J Exp Med. 2003 Nov 17;198(10):1527-37 [14623908.001]
  • [Cites] J Exp Med. 2003 Dec 15;198(12):1785-96 [14676294.001]
  • [Cites] Eur J Immunol. 2004 Sep;34(9):2387-95 [15307171.001]
  • [Cites] Diabetes. 2004 Oct;53(10):2581-7 [15448087.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14580-5 [15340148.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):464-6 [3899830.001]
  • [Cites] Diabetologia. 1989 May;32(5):282-9 [2666213.001]
  • [Cites] Reg Immunol. 1990-1991;3(6):305-17 [2132756.001]
  • [Cites] Eur J Immunol. 1992 Mar;22(3):711-7 [1547817.001]
  • [Cites] J Immunol. 1993 May 1;150(9):4136-50 [7682590.001]
  • [Cites] Annu Rev Immunol. 1993;11:501-38 [8476571.001]
  • [Cites] J Exp Med. 1994 Apr 1;179(4):1379-84 [8145050.001]
  • [Cites] Cell. 1994 Aug 12;78(3):399-408 [7520367.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2260-3 [8637860.001]
  • [Cites] J Exp Med. 1996 Nov 1;184(5):2049-53 [8920894.001]
  • [Cites] Diabetes. 1997 Jun;46(6):941-6 [9166663.001]
  • [Cites] Int Immunol. 1997 Aug;9(8):1159-64 [9263013.001]
  • [Cites] J Exp Med. 1998 Feb 2;187(3):427-32 [9449722.001]
  • [Cites] Autoimmunity. 1997;26(4):215-21 [9543182.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13009-14 [18755889.001]
  • [Cites] Diabetes. 2008 Nov;57(11):3013-24 [18689692.001]
  • [Cites] Clin Exp Immunol. 2009 Feb;155(2):173-81 [19128359.001]
  • [Cites] J Immunol. 2009 Nov 15;183(10):6403-12 [19841184.001]
  • [Cites] Curr Opin Immunol. 2009 Dec;21(6):648-57 [19828300.001]
  • [Cites] N Engl J Med. 2009 Nov 26;361(22):2143-52 [19940299.001]
  • [Cites] Immunity. 2010 Jan 29;32(1):129-40 [20079667.001]
  • [Cites] J Immunol. 2010 Apr 1;184(7):3618-27 [20200274.001]
  • [Cites] J Immunol. 2010 Apr 1;184(7):3321-5 [20208006.001]
  • [Cites] Am J Transplant. 2010 Apr;10(4):796-801 [20199511.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7538-43 [9636185.001]
  • [Cites] J Immunol. 1998 Aug 1;161(3):1163-8 [9686575.001]
  • [Cites] J Immunol. 1998 Oct 15;161(8):3912-8 [9780157.001]
  • [Cites] J Exp Med. 1999 Jan 18;189(2):331-9 [9892615.001]
  • [Cites] Immunity. 1999 Apr;10(4):451-61 [10229188.001]
  • [Cites] J Immunol. 2005 Jan 15;174(2):680-7 [15634886.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2235-43 [15947095.001]
  • [Cites] J Exp Med. 2005 Nov 21;202(10):1387-97 [16301745.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17729-33 [16317068.001]
  • [Cites] J Exp Med. 2006 Aug 7;203(8):2021-31 [16880259.001]
  • [Cites] J Immunol. 2007 Jun 15;178(12):7868-78 [17548625.001]
  • (PMID = 20675587.001).
  • [ISSN] 1550-6606
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 085896; United Kingdom / Medical Research Council / / G120/854; United Kingdom / Medical Research Council / / G0802382; United Kingdom / Medical Research Council / / ; United Kingdom / Wellcome Trust / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Cell Adhesion Molecule-1; 9006-59-1 / Ovalbumin
  • [Other-IDs] NLM/ EMS58025; NLM/ PMC3983558
  •  go-up   go-down


3. Wente MN, Schmied BM, Schmidt J, Büchler MW: [Differentiated therapy for intraductal papillary mucinous neoplasms]. Chirurg; 2009 Jan;80(1):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intraductal papillary mucinous neoplasms (IPMN) of the pancreas are of increasing interest in the field of pancreatic surgery ever since their first description as an individual pancreatic tumor entity in 1982.
  • Invasive IPMN forms (carcinoma in situ and invasive carcinoma) and in particular noninvasive IPMNs (adenoma and borderline tumors) reveal significantly better survival rates than ductal adenocarcinoma of the pancreas.
  • [MeSH-major] Adenocarcinoma, Mucinous / surgery. Carcinoma, Pancreatic Ductal / surgery. Carcinoma, Papillary / surgery. Pancreatectomy / methods. Pancreatic Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Carcinoma in Situ / diagnosis. Carcinoma in Situ / mortality. Carcinoma in Situ / pathology. Carcinoma in Situ / surgery. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Staging. Pancreas / pathology. Prognosis. Radiography, Dual-Energy Scanned Projection. Survival Rate. Tomography, Spiral Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Minerva Chir. 2004 Apr;59(2):185-207 [15238892.001]
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Am J Surg. 1999 Oct;178(4):344-7 [10587197.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Gut. 2008 Mar;57(3):287-9 [18268051.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):284-94 [18223495.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Eur J Surg Oncol. 2007 Aug;33(6):678-84 [17207960.001]
  • [Cites] Am J Surg Pathol. 2001 May;25(5):579-86 [11342768.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Lancet. 2005 Jan 8-14;365(9454):153-65 [15639298.001]
  • [Cites] Ann Surg. 2007 Dec;246(6):966-74; discussion 974-5 [18043098.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 1999 Jan;23 (1):1-16 [9888699.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer Control. 2008 Oct;15(4):322-33 [18813200.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] Gut. 2008 Nov;57(11):1490-1 [18941002.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):414-6 [17968632.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] J Clin Pathol. 2008 Dec;61(12):1303-13 [18703569.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2007 Sep;104(9):1338-43 [17827904.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Gut. 2002 Jun;50(6):861-8 [12010891.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] J Gastrointest Surg. 2008 Mar;12(3):401-4 [17957438.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • (PMID = 19082569.001).
  • [ISSN] 1433-0385
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 50
  •  go-up   go-down


Advertisement
4. Farnell MB: Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. J Gastrointest Surg; 2008 Mar;12(3):414-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical management of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • Intraductal papillary mucinous neoplasm (IPMN) of the pancreas is characterized by papillary growths within the pancreatic ductal system that are at risk for undergoing malignant transformation.
  • When operation is indicated, targeted pancreatic resection with frozen-section analysis of margins is recommended.
  • Survival following pancreatic resection for noninvasive IPMN is excellent.
  • The risk of recurrence following pancreatic resection for invasive IPMN is significant.
  • Surveillance is warranted both for patients subjected to pancreatic resection and for those under observation with side branch IPMN.
  • Much is yet to be learned regarding this neoplasm, and surgical management remains in evolution.
  • [MeSH-major] Adenoma / surgery. Carcinoma in Situ / surgery. Carcinoma, Pancreatic Ductal / surgery. Pancreatectomy. Pancreatic Neoplasms / surgery. Precancerous Conditions / surgery
  • [MeSH-minor] Carcinoma, Papillary / surgery. Diagnostic Imaging. Dilatation, Pathologic. Humans. Pancreatic Ducts / pathology. Pancreaticoduodenectomy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):441-5 [10685747.001]
  • [Cites] Surgery. 2000 May;127(5):536-44 [10819062.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] J Gastrointest Surg. 2005 Nov;9(8):1059-66; discussion 1066-7 [16269376.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1330-6 [15131794.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] J Clin Gastroenterol. 2006 Oct;40(9):856-62 [17016145.001]
  • [Cites] J Gastrointest Surg. 2003 Mar-Apr;7(3):417-28 [12654569.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Am J Surg. 1998 May;175(5):426-32 [9600293.001]
  • [Cites] Acta Cytol. 1991 Jul-Aug;35(4):456-63 [1718115.001]
  • (PMID = 17968632.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


5. Chu K, Tsai MJ: Neuronatin, a downstream target of BETA2/NeuroD1 in the pancreas, is involved in glucose-mediated insulin secretion. Diabetes; 2005 Apr;54(4):1064-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronatin, a downstream target of BETA2/NeuroD1 in the pancreas, is involved in glucose-mediated insulin secretion.
  • BETA2 plays an important role in the development of the pancreas and the nervous system.
  • Using microarray technology, we identified neuronatin (Nnat) as differentially expressed between wild-type (WT) and knockout (KO) pancreatic RNA from embryonic day 14 (e14.5).
  • Northern blot and in situ hybridization analysis of WT and KO samples confirmed the downregulation of Nnat in pancreas of mutant BETA2 embryos.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Institute for Transcriptional Informatics. gene/protein/disease-specific - Institute for Transcriptional Informatics (registration required).
  • Hazardous Substances Data Bank. GLUCOSE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diabetes. 1999 Mar;48(3):552-6 [10078555.001]
  • [Cites] Diabetes. 1999 Feb;48(2):416-9 [10334323.001]
  • [Cites] Genes Dev. 1999 Jul 1;13(13):1647-52 [10398678.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):323-8 [10545951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):865-70 [10639171.001]
  • [Cites] Diabetes. 2000 May;49(5):876-8 [10905500.001]
  • [Cites] Genes Dev. 2000 Nov 15;14(22):2839-54 [11090132.001]
  • [Cites] Development. 2001 Feb;128(3):417-26 [11152640.001]
  • [Cites] Diabetes Care. 2001 Aug;24(8):1438-41 [11473083.001]
  • [Cites] Dev Biol. 2001 Aug 15;236(2):387-99 [11476579.001]
  • [Cites] Diabetologia. 2001 Nov;44(11):2098-103 [11719843.001]
  • [Cites] Development. 2002 Feb;129(4):831-42 [11861467.001]
  • [Cites] Genomics. 2002 Mar;79(3):402-12 [11863370.001]
  • [Cites] Mol Endocrinol. 2002 Mar;16(3):541-51 [11875114.001]
  • [Cites] J Nutr. 2002 Mar;132(3):357-64 [11880555.001]
  • [Cites] Nat Genet. 2002 Apr;30(4):430-5 [11912494.001]
  • [Cites] J Mol Cell Cardiol. 2002 Aug;34(8):897-918 [12234762.001]
  • [Cites] J Neurosci. 2003 Jan 15;23(2):453-61 [12533605.001]
  • [Cites] FEBS Lett. 2003 Jun 12;545(1):76-85 [12788495.001]
  • [Cites] Acta Diabetol. 2003 Jun;40(2):109-11 [12861411.001]
  • [Cites] Mol Cell. 2003 Sep;12(3):723-34 [14527417.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2004 Mar;45(3):1009-19 [14985324.001]
  • [Cites] Mol Endocrinol. 2004 Apr;18(4):995-1003 [14726486.001]
  • [Cites] Biochem Biophys Res Commun. 1994 Jun 30;201(3):1227-34 [8024565.001]
  • [Cites] Science. 1995 May 12;268(5212):836-44 [7754368.001]
  • [Cites] Genes Dev. 1995 Apr 15;9(8):1009-19 [7774807.001]
  • [Cites] Dev Biol. 1995 Sep;171(1):73-84 [7556909.001]
  • [Cites] Brain Res. 1995 Aug 28;690(1):92-8 [7496812.001]
  • [Cites] Brain Res Dev Brain Res. 1996 Dec 23;97(2):185-93 [8997503.001]
  • [Cites] Endocrinology. 1997 Apr;138(4):1419-26 [9075697.001]
  • [Cites] Nucleic Acids Res. 1997 Sep 1;25(17):3428-32 [9254699.001]
  • [Cites] Genes Dev. 1997 Sep 15;11(18):2323-34 [9308961.001]
  • [Cites] Dev Biol. 1997 Oct 1;190(1):66-77 [9331332.001]
  • [Cites] J Biol Chem. 1998 Aug 7;273(32):19945-54 [9685329.001]
  • [Cites] EMBO J. 1998 Nov 16;17(22):6701-13 [9822613.001]
  • [Cites] Development. 1999 Jan;126(1):23-36 [9834183.001]
  • (PMID = 15793245.001).
  • [ISSN] 0012-1797
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD017379; United States / NICHD NIH HHS / HD / R37 HD017379; United States / NICHD NIH HHS / HD / HD-17379
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / DNA-Binding Proteins; 0 / Insulin; 0 / Membrane Proteins; 0 / Nerve Tissue Proteins; 0 / Neurod1 protein, mouse; 0 / Nnat protein, mouse; 0 / RNA, Small Interfering; 0 / Trans-Activators; IY9XDZ35W2 / Glucose
  • [Other-IDs] NLM/ NIHMS2527; NLM/ PMC1197706
  •  go-up   go-down


6. Schima W, Ba-Ssalamah A, Plank C, Kulinna-Cosentini C, Püspök A: [Pancreas. Part I: congenital changes, acute and chronic pancreatitis]. Radiologe; 2006 Apr;46(4):321-35; quiz 336
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreas. Part I: congenital changes, acute and chronic pancreatitis].
  • [Transliterated title] Pankreas. Teil I: Angeborene Veränderungen, akute und chronische Pankreatitis.
  • The pancreas develops from ventral and the dorsal buds, which undergo fusion.
  • Failure to fuse results in pancreas divisum, which is defined by separate pancreatic ductal systems draining into the duodenum.
  • Risk of developing pancreatitis is increased in pancreas divisum because of insufficient drainage.
  • MR cholangiopancreatography (MRCP) is the technique of choice for detecting pancreas divisum non-invasively.
  • Annular pancreas is the result of incomplete rotation of the pancreatic bud around the duodenum with the persistence of parenchyma or a fibrous band encircling (and sometimes stenosing) the duodenum.
  • Chronic pancreatitis results in relentless and irreversible loss of exocrine (and sometimes endocrine) function of the pancreas.
  • Inflammatory pseudotumor in chronic pancreatitis and groove pancreatitis are difficult to differentiate from pancreatic cancer.
  • In these cases, multiple imaging methods such as MDCT, MRI and endosonography including biopsy may be used to make a diagnosis.
  • [MeSH-major] Cholangiopancreatography, Magnetic Resonance / methods. Image Enhancement / methods. Pancreatitis / congenital. Pancreatitis / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] AJR Am J Roentgenol. 2002 Sep;179(3):717-24 [12185052.001]
  • [Cites] Radiology. 1990 Feb;174(2):331-6 [2296641.001]
  • [Cites] Scand J Gastroenterol. 1994 Oct;29(10 ):949-60 [7839103.001]
  • [Cites] JOP. 2005 Jan 13;6(1 Suppl):102-7 [15650293.001]
  • [Cites] Eur Radiol. 1998;8(7):1236-44 [9724445.001]
  • [Cites] Gastroenterol Jpn. 1987 Feb;22(1):92-9 [3569755.001]
  • [Cites] Radiology. 1994 Nov;193(2):297-306 [7972730.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):587-92 [9247480.001]
  • [Cites] Radiology. 1985 Sep;156(3):767-72 [4023241.001]
  • [Cites] Radiologe. 1996 May;36(5):413-8 [8778926.001]
  • [Cites] N Engl J Med. 1993 May 20;328(20):1433-7 [8479461.001]
  • [Cites] Radiol Clin North Am. 1989 Jan;27(1):39-50 [2642274.001]
  • [Cites] JOP. 2003 Sep;4(5):165-8 [14526127.001]
  • [Cites] Radiology. 1999 Jan;210(1):97-101 [9885593.001]
  • [Cites] Radiology. 2001 Oct;221(1):107-16 [11568327.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1199-209 [12479706.001]
  • [Cites] Radiology. 1996 Jun;199(3):697-701 [8637990.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):193-8 [10397125.001]
  • [Cites] Radiologe. 1996 May;36(5):381-8 [8778922.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):119-23 [9207510.001]
  • [Cites] Pancreas. 1993 May;8(3):358-61 [8483878.001]
  • [Cites] J Comput Assist Tomogr. 2005 Jul-Aug;29(4):452-60 [16012299.001]
  • [Cites] Radiology. 1998 Aug;208(2):537-42 [9680589.001]
  • [Cites] J Comput Assist Tomogr. 1998 Jul-Aug;22(4):651-5 [9676462.001]
  • [Cites] Radiology. 2000 May;215(2):358-64 [10796908.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):689-93 [11222206.001]
  • [Cites] Radiology. 2000 Nov;217(2):403-8 [11058635.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jan;156(1):93-5 [1898576.001]
  • [Cites] Radiol Clin North Am. 2002 Dec;40(6):1211-27 [12479707.001]
  • (PMID = 16496105.001).
  • [ISSN] 0033-832X
  • [Journal-full-title] Der Radiologe
  • [ISO-abbreviation] Radiologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 33
  •  go-up   go-down


7. Skowronek J, Sowier A, Skrzywanek P: Trans-hepatic technique and intraluminal Pulsed Dose Rate (PDR-BT) brachytherapy in treatment of locally advanced bile duct and pancreas cancer. J Contemp Brachytherapy; 2009 Jun;1(2):97-104
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trans-hepatic technique and intraluminal Pulsed Dose Rate (PDR-BT) brachytherapy in treatment of locally advanced bile duct and pancreas cancer.
  • PURPOSE: To assess the feasibility of intraluminal palliative Pulsed Dose Rate (PDR-BT) brachytherapy in the treatment of locally advanced bile duct and pancreas cancer.
  • MATERIAL AND METHODS: Forty-eight patients with advanced bile duct or pancreas cancer, disqualified from surgery or radical external beam radiation therapy (EBRT), were treated with trans-hepatic technique and intraluminal PDR-BT: 29 patients with bile duct cancer and 19 - pancreas cancer.
  • Target volume encompassed tumor visualized at cholangiography with one or two cm margin measured proximally and distally.
  • In 19 out of 29 (65.5%) of bile duct cancer cases and in 10 out of 19 (52.6%) of pancreas cancer patients clinical improvement (decrease of jaundice) was noted in first control after 4 weeks.
  • Median overall survival time (OS) for bile ducts cancer patients was 11.2 months and for pancreas cancer patients - 5.2 months.
  • 2. In most cases a satisfied palliative effect was achieved, however it was more apparent in bile duct cancer patients then in pancreas cancer patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27795719.001).
  • [ISSN] 1689-832X
  • [Journal-full-title] Journal of contemporary brachytherapy
  • [ISO-abbreviation] J Contemp Brachytherapy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Keywords] NOTNLM ; PDR brachytherapy / bile duct cancer / pancreas cancer
  •  go-up   go-down


8. Rangel EB, Melaragno CS, Neves MD, Dib SA, Gonzalez AM, Linhares MM, Pacheco-Silva A, Sá JR: Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant. Exp Clin Transplant; 2010 Mar;8(1):29-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Family history of diabetes as a new determinant of insulin sensitivity and secretion in patients who have undergone a simultaneous pancreas-kidney transplant.
  • OBJECTIVES: We used homeostasis model assessment to investigate insulin sensitivity and secretion after a simultaneous pancreas-kidney transplant or kidney transplant alone.
  • MATERIALS AND METHODS: Factors (eg, age, sex, race, delayed kidney allograft function) were correlated with homeostasis model assessment of beta-cell function and homeostasis model assessment of insulin sensitivity values after simultaneous pancreas-kidney transplant (n=89) or kidney transplant alone (n=68), and the results were compared with those in healthy subjects (n=49).
  • RESULTS: Homeostasis model assessment of beta-cell function values were similar in patients who underwent kidney transplant alone or a simultaneous pancreas-kidney transplant, and were higher than homeostasis model assessment of beta cell function values in healthy subjects.
  • The homeostasis model assessment of insulin sensitivity showed intermediate values for patients who underwent a simultaneous pancreas-kidney transplant and correlated with prednisone dosages (in those who underwent kidney transplant alone) and tacrolimus levels (in patients who underwent a simultaneous pancreas-kidney transplant).
  • Homeostasis model assessment of beta-cell function values correlated with prednisone dosages in both groups and with tacrolimus levels in only those who underwent a simultaneous pancreas-kidney transplant.
  • A family history of diabetes in subjects who underwent a simultaneous pancreas-kidney transplant correlated with homeostasis model assessment of beta-cell function results and homeostasis model assessment of insulin sensitivity results.
  • A family history of diabetes was linked with higher values of insulin secretion and lower insulin sensitivity in patients who underwent a simultaneous pancreas-kidney transplant.
  • [MeSH-major] Diabetes Mellitus / genetics. Insulin / secretion. Insulin Resistance / physiology. Kidney Transplantation / physiology. Pancreas Transplantation / physiology. Pedigree

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199368.001).
  • [ISSN] 2146-8427
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Turkey
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Immunosuppressive Agents; 0 / Insulin; VB0R961HZT / Prednisone; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down


9. Hering R, Bolten JC, Kreyer S, Berg A, Wrigge H, Zinserling J, Putensen C: Spontaneous breathing during airway pressure release ventilation in experimental lung injury: effects on hepatic blood flow. Intensive Care Med; 2008 Mar;34(3):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During APRV with SB blood flow (ml g(-1) min(-1)) was 0.91+/-0.26 (hepatic arterial), 0.29+/-0.05 (stomach), 0.64+/-0.08 (duodenum), 0.62+/-0.10 (jejunum), 0.53+/-0.07 (ileum), 0.53+/-0.07 (colon), 0.46+/-0.09 (pancreas) and 3.59+/-0.55 (spleen).
  • During APRV without SB applying high P(aw) it decreased to 0.13+/-0.01 (stomach), 0.37+/-0.03 (duodenum), 0.29+/-0.03 (jejunum), 0.31+/-0.05 (ileum), 0.32+/-0.03 (colon) and 0.23+/-0.04 (pancreas) p<0.01, respectively.
  • During APRV without SB applying same Paw limits it decreased to 0.18+/-0.03 (stomach, p<0.01), 0.47+/-0.06 (duodenum, p<0.05), 0.38+/-0.05 (jejunum, p<0.01), 0.36+/-0.03 (ileum, p<0.05), 0.39+/-0.05 (colon, p<0.05), and 0.27+/-0.04 (pancreas, p<0.01).

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • Hazardous Substances Data Bank. OLEIC ACID .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intensive Care Med. 2008 Mar;34(3):397-9 [18087690.001]
  • [Cites] Arch Surg. 1976 Aug;111(8):881-3 [942299.001]
  • [Cites] Am J Physiol. 1979 Jul;237(1):H25-33 [464066.001]
  • [Cites] Intensive Care Med. 1997 May;23(5):493-503 [9201520.001]
  • [Cites] Circulation. 1991 Mar;83(3):974-82 [1999045.001]
  • [Cites] Chest. 1997 Jan;111(1):180-7 [8996014.001]
  • [Cites] Pflugers Arch. 1983 Nov;399(3):223-7 [6657464.001]
  • [Cites] J Appl Physiol (1985). 1995 Apr;78(4):1319-29 [7615439.001]
  • [Cites] Am J Physiol. 1985 Nov;249(5 Pt 1):G549-56 [3904482.001]
  • [Cites] J Appl Physiol (1985). 1987 Apr;62(4):1377-83 [2954939.001]
  • [Cites] Am J Physiol. 1994 Oct;267(4 Pt 2):H1233-42 [7943366.001]
  • [Cites] Intensive Care Med. 2002 Oct;28(10):1426-33 [12373467.001]
  • [Cites] Crit Care Med. 1987 May;15(5):462-6 [3552443.001]
  • [Cites] Crit Care Med. 1987 Feb;15(2):106-13 [3542385.001]
  • [Cites] J Physiol. 2001 Feb 15;531(Pt 1):193-201 [11179403.001]
  • [Cites] Anesthesiology. 2003 Nov;99(5):1137-44 [14576551.001]
  • [Cites] Adv Exp Med Biol. 1998;454:435-40 [9889921.001]
  • [Cites] Am J Respir Crit Care Med. 1995 Aug;152(2):504-10 [7633699.001]
  • (PMID = 18087691.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 2UMI9U37CP / Oleic Acid; S88TT14065 / Oxygen
  •  go-up   go-down


10. Nishino T, Toki F, Oyama H, Shimizu K, Shiratori K: Long-term outcome of autoimmune pancreatitis after oral prednisolone therapy. Intern Med; 2006;45(8):497-501
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: We investigated the long-term outcome of autoimmune pancreatitis (AIP) including morphological changes in the pancreas, pancreatic duct, biliary tract, pancreatic function, and changes in the clinical manifestations after oral prednisolone (PSL) therapy.
  • The morphological findings consisted of pancreatic enlargement (n=12), an irregularly narrowed main pancreatic duct (n=12), and bile duct stricture (n=10), and salivary gland swelling was observed in six patients.
  • The enlargement of the pancreas and the irregularly narrowed main pancreatic duct improved to almost normal.
  • Pancreatic atrophy developed in four of them (4/12, 33%), but no pancreatic calcification was observed in any of the patients.
  • There was no recurrence of enlargement of the pancreas or irregularly narrowed main pancreatic duct after PSL therapy, but the bile duct stricture recurred in one case, and in three cases there was a relapse of salivary gland swelling that required a temporary increase in PSL dose during tapering.
  • No deterioration of pancreatic exocrine function was detected in any of the patients.
  • A malignant tumor was diagnosed in two patients during PSL therapy: early gastric cancer in one and rectal cancer in the other.
  • CONCLUSIONS: AIP treated with PSL has a favorable long-term outcome based on the morphological findings and assessments of pancreatic function.
  • [MeSH-minor] Administration, Oral. Aged. Biliary Tract / pathology. Cholangiopancreatography, Endoscopic Retrograde. Female. Humans. Immunoglobulin G / blood. Male. Middle Aged. Pancreatic Ducts / pathology. Pancreatic Function Tests. Salivary Glands / pathology. Sjogren's Syndrome / diagnosis. Tomography, X-Ray Computed


11. Jia D, Taguchi M, Otsuki M: Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats. Pancreas; 2005 Jan;30(1):54-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventive and therapeutic effects of the protease inhibitor camostat on pancreatic fibrosis and atrophy in CCK-1 receptor-deficient rats.
  • OBJECTIVES: Recent studies have demonstrated that synthetic protease inhibitors could ameliorate the progression of pancreatic fibrosis in some animal models.
  • Since oral administration of protease inhibitors increases the plasma cholecystokinin (CCK) levels and causes hypertrophy of the pancreas in rats, there is a possibility that the protease inhibitor inhibits fibrosis in the pancreas via endogenous CCK release.
  • We examined the effects of camostat, a synthetic protease inhibitor, on histopathologic changes in Otsuka Long-Evans Tokushima Fatty (OLETF) rat that has genetically no expression of CCK-1 receptor and displays inflammation and degeneration of the pancreas.
  • RESULTS: Pancreatic wet weight and pancreatic contents of protein, DNA, amylase, lipase, and trypsin in camostat-treated rats were significantly higher than those in the untreated control rats.
  • Immunohistochemical studies of the pancreas showed that expressions of interleukin-1beta, interleukin-6, tumor necrosis factor-alpha, and alpha-smooth muscle actin in camostat-treated rats were greatly suppressed compared with those in the untreated control rats.
  • Atrophy and fibrosis in the pancreas observed in the untreated control rats were not found in camostat-fed rats.
  • CONCLUSION: The results of the present study suggest that camostat greatly inhibits pancreatic inflammation and prevents and reverses fibrosis and atrophy of the pancreas in the genetically obese and CCK-1 receptor-deficient OLETF rats.
  • [MeSH-minor] Actins / metabolism. Amylases / metabolism. Animals. Atrophy. Eating. Fibrosis. Interleukin-6 / metabolism. Lipase / metabolism. Male. Obesity / complications. Organ Size. Pancreas / enzymology. Pancreas / pathology. Rats. Rats, Inbred OLETF. Transforming Growth Factor beta / metabolism. Trypsin / metabolism. Tumor Necrosis Factor-alpha / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15632700.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Interleukin-6; 0 / Protease Inhibitors; 0 / Receptor, Cholecystokinin A; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 0FD207WKDU / camostat; 4V7M9137X9 / Gabexate; EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases; EC 3.4.21.4 / Trypsin
  •  go-up   go-down


12. Cross SE, Hughes SJ, Partridge CJ, Clark A, Gray DW, Johnson PR: Collagenase penetrates human pancreatic islets following standard intraductal administration. Transplantation; 2008 Oct 15;86(7):907-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collagenase penetrates human pancreatic islets following standard intraductal administration.
  • The aim of this study was to characterize collagenase distribution in relation to islets in infused human pancreases.
  • METHODS: : Human pancreases were retrieved from multiorgan donors with appropriate consent.
  • RESULTS: : Collagenase labeling was widespread throughout the pancreas, associated with collagen VI, and adjacent to CK19-labeled ducts.
  • Intraislet collagenase was observed in 70%+/-3% of islets in the pancreatic tail, compared with 58%+/-2% and 53%+/-2% of islets in the body and neck, respectively (P<0.05 tail vs. neck), and was more prevalent in islets with diameters more than 150 microm (98%+/-1% of islets >150 microm vs. 52%+/-2% of islets <150 microm, P<0.05).
  • There was no difference in intraislet collagenase labeling between perfused and syringe-loaded pancreases.
  • [MeSH-minor] Drug Administration Routes. Humans. Organ Preservation Solutions. Pancreas / anatomy & histology. Pancreas / enzymology. Pancreas, Exocrine / enzymology. Pancreatic Ducts / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852654.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Organ Preservation Solutions; EC 3.4.24.- / Collagenases
  •  go-up   go-down


13. Atias S, Mizrahi SS, Shaco-Levy R, Yussim A: Preservation of pancreatic tissue morphology, viability and energy metabolism during extended cold storage in two-layer oxygenated University of Wisconsin/perfluorocarbon solution. Isr Med Assoc J; 2008 Apr;10(4):273-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preservation of pancreatic tissue morphology, viability and energy metabolism during extended cold storage in two-layer oxygenated University of Wisconsin/perfluorocarbon solution.
  • BACKGROUND: In contrast to the relative scarcity of donor kidneys and hearts, the potential supply of deceased donor pancreata is exceeding the demand.
  • However, this organ surplus is not being fully realized because, in current transplantation practice, the duration of pancreas storage before transplantation is limited to 8-10 hours due to the extreme vulnerability of pancreatic tissue to anaerobic damage caused by preservation.
  • OBJECTIVES: To reduce cold ischemic injury in order to increase the utilization of donor pancreases in Israel for whole-organ and cell transplantation.
  • METHODS: We evaluated a novel two-layer preservation oxygenated cold storage method that uses perfluorocarbon to continuously supply oxygen to the pancreas during preservation in conventional University of Wisconsin solution.
  • RESULTS: Pancreatic tissue morphology, viability and adenosine-triphosphate content were serially examined during preservation of the pig pancreas for 24 hours either by a two-layer or by conventional simple cold storage.
  • CONCLUSIONS: The UW/PFC two-layer preservation method allowed tissue ATP synthesis and amelioration of cold ischemic tissue damage during extended 24 hour pancreas preservation.
  • This method could be implemented in clinical practice to maximize utilization of pancreata for whole-organ and islet transplantation as well as for pancreas sharing with remote centers.
  • [MeSH-major] Cryopreservation / methods. Fluorocarbons. Organ Preservation / methods. Pancreas

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18548980.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Organ Preservation Solutions; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


14. Malaise J, Secchi A, Caldara R, Tydén G, Sandberg J, Van Ophem D, Squifflet JP, EUROSPK Study Group: Metabolic assessment after simultaneous pancreas-kidney transplantation. Transplant Proc; 2005 Jul-Aug;37(6):2851-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metabolic assessment after simultaneous pancreas-kidney transplantation.
  • Simultaneous pancreas-kidney (SPK) transplantation has become a standard therapy for patients with type 1 diabetes and end-stage renal disease.
  • PATIENTS AND METHODS: We analyzed 205 patients enrolled in the Euro-SPK001 study for fasting blood glucose, fasting C peptide, glycated hemoglobin (HbA(1c)), blood lipids (total cholesterol and triglycerides), and pancreatic enzymes at regular intervals during the study.
  • [MeSH-major] Hemoglobin A, Glycosylated / analysis. Kidney Transplantation / physiology. Pancreas Transplantation / physiology

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - A1C.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182831.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / C-Peptide; 0 / Hemoglobin A, Glycosylated; 0 / Immunosuppressive Agents; 0 / Lipids; EC 3.2.1.- / Amylases
  •  go-up   go-down


15. Ye R, Mareninova OA, Barron E, Wang M, Hinton DR, Pandol SJ, Lee AS: Grp78 heterozygosity regulates chaperone balance in exocrine pancreas with differential response to cerulein-induced acute pancreatitis. Am J Pathol; 2010 Dec;177(6):2827-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grp78 heterozygosity regulates chaperone balance in exocrine pancreas with differential response to cerulein-induced acute pancreatitis.
  • The endoplasmic reticulum (ER) is abundant in the acinar cells of the exocrine pancreas.
  • Exocrine pancreata of RD-fed Grp78(+/-) mice in an outbred C57BL/6 × 129/sv genetic background exhibited ER lumen dilation, a reduction in chaperones calnexin (CNX) and calreticulin (CRT), and exacerbated pancreatitis associated with high CHOP induction.
  • Thus, in exocrine pancreata, Grp78 heterozygosity regulates ER chaperone balance, in dietary- and genetic background-dependent manners, and improved ER protein folding capacity might be protective against pancreatitis.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3496-9 [17440054.001]
  • [Cites] Gastroenterology. 2007 Mar;132(3):1127-51 [17383433.001]
  • [Cites] Cell Death Differ. 2007 Jul;14(7):1285-94 [17431416.001]
  • [Cites] FEBS Lett. 2007 Jul 31;581(19):3641-51 [17481612.001]
  • [Cites] Mol Cell. 2007 Oct 12;28(1):41-56 [17936703.001]
  • [Cites] BMC Cell Biol. 2007;8:38 [17727724.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19989-94 [18056632.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):498-505 [18199545.001]
  • [Cites] J Biol Chem. 2008 Apr 18;283(16):10221-5 [18303019.001]
  • [Cites] Cell Death Differ. 2008 Sep;15(9):1460-71 [18551133.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Dec;295(6):G1190-201 [18845574.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 9;105(49):19444-9 [19033462.001]
  • [Cites] Cell Metab. 2009 Jan 7;9(1):35-51 [19117545.001]
  • [Cites] Biochem J. 2009 Feb 1;417(3):651-66 [19133842.001]
  • [Cites] Dev Biol. 2009 Feb 1;326(1):4-35 [19013144.001]
  • [Cites] Hum Mutat. 2009 Apr;30(4):575-82 [19191323.001]
  • [Cites] Parkinsonism Relat Disord. 2009 Nov;15(9):649-54 [19345133.001]
  • [Cites] World J Gastroenterol. 2009 Nov 14;15(42):5260-5 [19908332.001]
  • [Cites] Antioxid Redox Signal. 2009 Sep;11(9):2307-16 [19309259.001]
  • [Cites] J Lipid Res. 2009 Dec;50(12):2486-501 [19461119.001]
  • [Cites] Cell Death Differ. 2010 Mar;17(3):488-98 [19816510.001]
  • [Cites] Gut. 2010 Mar;59(3):365-72 [19951900.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2010 May;298(5):E1027-35 [20159858.001]
  • [Cites] Proc Soc Exp Biol Med. 2000 Mar;223(3):310-5 [10719845.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5096-106 [10866666.001]
  • [Cites] Mol Cell. 2001 Jun;7(6):1153-63 [11430819.001]
  • [Cites] Biochem J. 2002 Sep 15;366(Pt 3):787-95 [12076252.001]
  • [Cites] Biol Rev Camb Philos Soc. 1978 May;53(2):211-354 [208670.001]
  • [Cites] Dig Dis Sci. 1986 Jul;31(7):779-80 [2424680.001]
  • [Cites] Gut. 1992 Jul;33(7):982-6 [1379569.001]
  • [Cites] J Biol Chem. 1995 Apr 21;270(16):9526-34 [7721881.001]
  • [Cites] Am J Physiol. 1996 Jan;270(1 Pt 1):G128-35 [8772510.001]
  • [Cites] Gastroenterology. 1996 Oct;111(4):1081-91 [8831604.001]
  • [Cites] Cell Stress Chaperones. 1996 Jun;1(2):109-15 [9222596.001]
  • [Cites] J Biol Chem. 1997 Dec 5;272(49):30873-9 [9388233.001]
  • [Cites] Mt Sinai J Med. 2004 Oct;71(5):289-97 [15543429.001]
  • [Cites] Biophys J. 2004 Dec;87(6):L03-5 [15516519.001]
  • [Cites] Methods. 2005 Apr;35(4):373-81 [15804610.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1111-9 [15864338.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5785-91 [15994954.001]
  • [Cites] Clin Chim Acta. 2005 Dec;362(1-2):26-48 [16024009.001]
  • [Cites] J Biol Chem. 2006 Feb 10;281(6):3370-81 [16339139.001]
  • [Cites] Cell. 2006 Feb 10;124(3):587-99 [16469704.001]
  • [Cites] J Neurochem. 2006 Jun;97(5):1259-68 [16539653.001]
  • [Cites] J Clin Invest. 2006 Jul;116(7):1793-801 [16823477.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Aug;291(2):G238-45 [16574987.001]
  • [Cites] Mol Cell Biol. 2006 Aug;26(15):5688-97 [16847323.001]
  • [Cites] Curr Opin Gastroenterol. 2006 Sep;22(5):481-6 [16891878.001]
  • [Cites] Science. 2006 Aug 25;313(5790):1137-40 [16931765.001]
  • [Cites] PLoS Biol. 2006 Nov;4(11):e374 [17090218.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):190-207 [17241871.001]
  • [Cites] FEBS J. 2007 Feb;274(3):630-58 [17288551.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1804-12 [17431218.001]
  • (PMID = 20971738.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA16010; United States / NIAAA NIH HHS / AA / AA11999; United States / NIDDK NIH HHS / DK / DK070582; United States / NIAAA NIH HHS / AA / R21 AA016010; United States / NCI NIH HHS / CA / R01 CA027607; United States / NIDDK NIH HHS / DK / R21 DK070582; United States / NIDDK NIH HHS / DK / P30 DK048522; United States / NCI NIH HHS / CA / CA027607; United States / NIAAA NIH HHS / AA / P50 AA011999; United States / NIDDK NIH HHS / DK / DK048522
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Gastrointestinal Agents; 0 / Heat-Shock Proteins; 0 / Molecular Chaperones; 0 / molecular chaperone GRP78; 888Y08971B / Ceruletide
  • [Other-IDs] NLM/ PMC2993313
  •  go-up   go-down


16. Seki M, Ninomiya E, Takano K, Fujita R, Aruga A, Yamada K, Tanaka H, Matsueda K, Mikami K, Hiki N, Saiura A, Yamamoto J, Yamaguchi T, Yanagisawa A, Ikeda M, Sasaki K, Kato Y: Pancreatogram findings for carcinoma in situ (CIS) of the pancreas seen on endoscopic retrograde cholangiopancreatography and postoperative pancreatography of resected specimens: can CIS be diagnosed preoperatively? Pancreatology; 2008;8(2):142-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatogram findings for carcinoma in situ (CIS) of the pancreas seen on endoscopic retrograde cholangiopancreatography and postoperative pancreatography of resected specimens: can CIS be diagnosed preoperatively?
  • In addition, 7 of 79 invasive ductal carcinomata (IDC) of the pancreas were accompanied by CIS > or =2 cm long.
  • A total of 11 patients were reviewed here for pancreatographic findings for CIS of the pancreas.
  • METHODS: All resected pancreatobiliary materials were sliced serially at 5- to 8-mm intervals in a plane at right angles to the main pancreatic duct, referring to POP images.
  • CONCLUSIONS: I, N, G, and D are most important pancreatographic findings in ERCP and highly suggestive of CIS of the pancreas, so that whenever they are encountered, cytological and/or pathological examination of the pancreatic duct should be actively performed.
  • [MeSH-major] Carcinoma in Situ / radiography. Cholangiopancreatography, Endoscopic Retrograde. Pancreas / radiography. Pancreatic Neoplasms / radiography
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Incidental Findings. Male. Middle Aged. Pancreatic Ducts / radiography. Postoperative Care. Preoperative Care

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18382100.001).
  • [ISSN] 1424-3911
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


17. Vinkers MT, Rahmel AO, Slot MC, Smits JM, Schareck WD: How to recognize a suitable pancreas donor: a Eurotransplant study of preprocurement factors. Transplant Proc; 2008 Jun;40(5):1275-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How to recognize a suitable pancreas donor: a Eurotransplant study of preprocurement factors.
  • INTRODUCTION: Because of the increasing demand for pancreas transplantation, more marginal donors are offered to Eurotransplant.
  • The aim of this study was to validate a donor quality score that would facilitate recognition of a suitable pancreas donor among all reported donors.
  • MATERIALS AND METHODS: We analyzed all 3180 consecutively reported pancreas donors for the period between January 1, 2002 and June 30, 2005 and determined the influence of the preprocurement pancreas suitability score (P-PASS) on the acceptance of a pancreas.
  • RESULTS: Multiple regression analysis using pancreas acceptance as an outcome variable identified P-PASS > or = 17 as a significant cutoff point (P < .001).
  • Pancreata from donors with P-PASS > or = 17 were three times more likely to be refused.
  • CONCLUSION: The donor score can help in screening for potential pancreas donors, where an ideal donor has a P-PASS < 17.
  • Our data demonstrate that consideration of a combination of preprocurement factors can help identify a suitable pancreas donor.
  • Therefore, we recommend that a pancreas donor score be calculated for each potential pancreas donor, and all donors with a P-PASS < 17 should be considered for pancreas donation.
  • [MeSH-major] Pancreas. Pancreas Transplantation / methods. Tissue Donors / statistics & numerical data. Tissue and Organ Procurement / methods

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18589086.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABO Blood-Group System
  •  go-up   go-down


18. Ulicna M, Danisovic L, Danihel L, Vojtassak J: Diabetes--adult stem cells as an future alternative therapy? Bratisl Lek Listy; 2009;110(12):773-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One way to achieve a constant normoglycemic state without hypoglycemic episodes is either whole pancreas transplantation, or transplantation of isolated islets of Langerhans.
  • Another approach to correct the beta-cell deficit is the stimulation of beta-cells in pancreas to regeneration.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20196471.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Slovakia
  • [Number-of-references] 47
  •  go-up   go-down


19. Kawamoto S, Lawler LP, Horton KM, Eng J, Hruban RH, Fishman EK: MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma. AJR Am J Roentgenol; 2006 Mar;186(3):687-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDCT of intraductal papillary mucinous neoplasm of the pancreas: evaluation of features predictive of invasive carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate factors predictive of the presence of invasive carcinoma associated with intraductal papillary mucinous neoplasm (IPMN) of the pancreas on MDCT.
  • MATERIALS AND METHODS: Preoperative MDCT of 36 consecutive patients (23 men, 13 women; mean age, 66.6 years) who had undergone surgical resection and had a pathologic diagnosis of IPMN were retrospectively assessed.
  • Type of ductal involvement, location, tumor size in branch duct type and combined type lesions, caliber of the main pancreatic duct, caliber of the common bile duct or common hepatic duct, and solid appearance of the lesion were assessed on CT and correlated with pathologic findings for invasive carcinoma.
  • With invasive carcinoma, the size of the tumor in branch duct type and combined type, and the caliber of the main pancreatic duct were significantly larger compared with the lesions without invasive carcinoma (4.7 +/- 1.7 cm vs 2.6 +/- 1.4 cm [p = 0.0007] and 9.3 +/- 5.5 mm vs 4.6 +/- 4.1 mm [p = 0.006], respectively).
  • [MeSH-major] Adenocarcinoma, Mucinous / radiography. Carcinoma, Pancreatic Ductal / radiography. Pancreatic Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498096.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


20. Mancuso F, Calvitti M, Luca G, Nastruzzi C, Baroni T, Mazzitelli S, Becchetti E, Arato I, Boselli C, Ngo Nselel MD, Calafiore R: Acceleration of functional maturation and differentiation of neonatal porcine islet cell monolayers shortly in vitro cocultured with microencapsulated sertoli cells. Stem Cells Int; 2010;2010:587213
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The limited availability of cadaveric human donor pancreata as well as the incomplete success of the Edmonton protocol for human islet allografts fasten search for new sources of insulin the producing cells for substitution cell therapy of insulin-dependent diabetes mellitus (T1DM).
  • Starting from isolated neonatal porcine pancreatic islets (NPIs), we have obtained cell monolayers that were exposed to microencapsulated monolayered Sertoli cells (ESCs) for different time periods (7, 14, 21 days).
  • The insulin/c-kit positive cells might represent a new, still unknown functionally immature β-cell like element in the porcine pancreas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048849.001).
  • [ISSN] 1687-9678
  • [Journal-full-title] Stem cells international
  • [ISO-abbreviation] Stem Cells Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2956457
  •  go-up   go-down


21. Siddique K, Ali Q, Mirza S, Jamil A, Ehsan A, Latif S, Malik AZ: Evaluation of the aetiological spectrum of obstructive jaundice. J Ayub Med Coll Abbottabad; 2008 Oct-Dec;20(4):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The surgical jaundice can be caused by the obstruction of the bile duct as with gall stones, strictures, malignancy, such as cholangiocarcinoma (in which the jaundice is persistent and progressive), periampullary carcinoma, carcinoma gall bladder and carcinoma head of pancreas.
  • Malignant obstructive jaundice was seen in 34 (56.66%) patients while 26 (43.33%) had benign etiology.
  • Amongst the commonest symptom; clay coloured stools (75%) was more frequent in patients with malignant disease whereas abdominal pain (51.66%) was most common in benign conditions.
  • Commonest malignancy was Carcinoma (Ca) of the head of pancreas 18/60 (30%) followed by Ca gall bladder 8/60 (13.33%), cholangiocarcinoma 7/60 (11.66%), and periampullary carcinoma 1/60 (1.66%).
  • Choledocholithiasis 21/60 (35%) was the commonest benign cause followed by stricture of common bile duct 3/60 (5%) and acute pancreatitis 2/60 (3.33%).
  • Ca head of pancreas is the commonest malignancy while Choledocholithiasis is the commonest benign cause.
  • [MeSH-major] Jaundice, Obstructive / diagnosis. Jaundice, Obstructive / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19999207.001).
  • [ISSN] 1025-9589
  • [Journal-full-title] Journal of Ayub Medical College, Abbottabad : JAMC
  • [ISO-abbreviation] J Ayub Med Coll Abbottabad
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


22. Leslie MA, Moran ET Jr, Bedford MR: The effect of phytase and glucanase on the ileal digestible energy of corn and soybean meal fed to broilers. Poult Sci; 2007 Nov;86(11):2350-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the end of each experimental period, the broilers were euthanized and the contents of the ileum, duodenum and jejunum (pooled), and pancreas were removed for analysis.
  • The pancreas and duodenal-jejunal samples were analyzed for proteolytic and amylase activity to determine the influence of practical levels of phytate on enzyme activity.
  • Results showed that neither phytase nor glucanase influenced enzyme activity in the digesta or pancreas, suggesting that practical levels of phytate did not influence the activity of proteolytic enzymes or amylase.
  • The IDE and DM digestibility of corn and the digesta and pancreatic enzyme activities increased with age, whereas the IDE of SBM was similar among age groups.
  • [MeSH-minor] Aging. Animal Nutritional Physiological Phenomena. Animals. Diet / veterinary. Dietary Supplements. Energy Metabolism / drug effects. Male. Pancreas. Soybeans / metabolism. Zea mays / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954585.001).
  • [ISSN] 0032-5791
  • [Journal-full-title] Poultry science
  • [ISO-abbreviation] Poult. Sci.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.1.3.26 / 6-Phytase; EC 3.2.1.- / Glycoside Hydrolases
  •  go-up   go-down


23. Andrades P, Asiedu C, Ray P, Rodriguez C, Goodwin J, McCarn J, Thomas JM: Islet yield after different methods of pancreatic Liberase delivery. Transplant Proc; 2007 Jan-Feb;39(1):183-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Islet yield after different methods of pancreatic Liberase delivery.
  • OBJECTIVE: Enzymatic digestion of the pancreas is a fundamental step in islet isolation and there are many ways to administer the enzyme during procurement.
  • The aim of this study was to evaluate the influence of different methods of Liberase delivery during pancreas harvest on the quality and quantity of islets.
  • After injection, the pancreata were harvested, digested in Liberase solution, mechanically disrupted, and purified using discontinuous gradient centrifugation.
  • CONCLUSION: Intraductal administration is the best enzyme delivery method for pancreatic islet isolation.
  • The pancreatic ducts are the most anatomic and physiological way to transport the enzyme uniformly inside the pancreas, determining an adequate digestion and better islet quantity and quality when compared with other delivery methods.
  • [MeSH-major] Collagenases. Islets of Langerhans / cytology. Pancreas / cytology. Thermolysin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17275501.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / R03 DK58965-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Collagenases; EC 3.4.24.- / Liberase; EC 3.4.24.27 / Thermolysin
  •  go-up   go-down


24. Miao G, Ito T, Uchikoshi F, Tanemura M, Kawamoto K, Shimada K, Nozawa M, Matsuda H: Development of islet-like cell clusters after pancreas transplantation in the spontaneously diabetic Torri rat. Am J Transplant; 2005 Oct;5(10):2360-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of islet-like cell clusters after pancreas transplantation in the spontaneously diabetic Torri rat.
  • Pancreas transplantation (PTx) has evolved as a clinical therapy to achieve sustained euglycemia.
  • However, it remains unclear if naive diseased islets of the pancreas benefit from the avoidance of glucose toxicity by PTx.
  • Moreover, we found that the beta-cell mass was significantly increased in the naive pancreases of 40-week-old PTx recipients (PTx40-naive).
  • Interestingly, islet-like cell clusters of varying size were found close to ductal structures of PTx40-naive pancreases, suggesting that these cells are derived from ductal cells.
  • Furthermore, pancreatic and duodenal homeobox factor-1 (PDX-1) was more clearly expressed in the nuclei of PTx40-naive pancreatic islet-like cell clusters.
  • Our results demonstrate the development of duct-derived beta cells in the pancreas of type 2 diabetic recipients after PTx.
  • [MeSH-major] Diabetes Mellitus, Experimental / pathology. Islets of Langerhans / cytology. Pancreas Transplantation / methods. Pancreas Transplantation / pathology
  • [MeSH-minor] Age of Onset. Animals. Blotting, Western. Cell Nucleus / metabolism. Cell Proliferation. Disease Models, Animal. Glucagon / chemistry. Glucose / pharmacology. Glucose / toxicity. Glucose Tolerance Test. Homeodomain Proteins / biosynthesis. Immunohistochemistry. Insulin / chemistry. Insulin / metabolism. Insulin / pharmacology. Insulin-Secreting Cells / cytology. Islets of Langerhans Transplantation / methods. Ki-67 Antigen / biosynthesis. Male. Pancreas / metabolism. Pancreas / pathology. Rats. Time Factors. Trans-Activators / biosynthesis

  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. GLUCAGON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16162183.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Insulin; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein; 9007-92-5 / Glucagon; IY9XDZ35W2 / Glucose
  •  go-up   go-down


25. Liao Z, Gao R, Wang W, Ye Z, Lai XW, Wang XT, Hu LH, Li ZS: A systematic review on endoscopic detection rate, endotherapy, and surgery for pancreas divisum. Endoscopy; 2009 May;41(5):439-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A systematic review on endoscopic detection rate, endotherapy, and surgery for pancreas divisum.
  • BACKGROUND AND STUDY AIMS: The rates for endoscopic detection of pancreas divisum at routine endoscopic retrograde cholangiopancreatography (ERCP) vary worldwide, and the sample sizes in the reported studies on endoscopy and surgery for pancreas divisum are very small and variable.
  • The aim of this study was to systematically analyze the pooled data and determine endoscopic detection rates for pancreas divisum and pain relief rates in patients with pancreas divisum after endotherapy or surgery.
  • MATERIALS AND METHODS: A search for published data was performed by using the Medline database (1950 to 1st May 2008) with "pancreas divisum" as the keyword.
  • Publications, mainly on endoscopic detection rate, endotherapy, or surgery for pancreas divisum, were deemed relevant, and were further fully reviewed and analyzed.
  • The overall endoscopic detection rate for pancreas divisum was 2.9% (899/31,413), with the rate being significantly higher in the United States (5.8%) and Europe (6.0%) than in Asia (1.5%) (both P < 0.001).
  • In addition, there were significant differences in the combined response rates (for endotherapy and for surgery) between patients with pancreas divisum of acute recurrent pancreatitis (ARP)-type (81.2 %) compared with chronic pancreatitis-type (68.8%), and between ARP-type and pain-type (53.1%) (both P < 0.05).
  • CONCLUSIONS: The endoscopic detection rate for pancreas divisum is much higher in western countries than in Asian countries.
  • The pooled response rates of patients with pancreas divisum to endotherapy and surgery are similar in the reported series.
  • Patients with ARP-type pancreas divisum respond better to endotherapy or surgery than those with chronic pancreatitis-type and pain-type.
  • [MeSH-major] Cholangiopancreatography, Endoscopic Retrograde. Pancreas / abnormalities. Pancreatitis, Acute Necrotizing / diagnosis. Pancreatitis, Chronic / diagnosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19337962.001).
  • [ISSN] 1438-8812
  • [Journal-full-title] Endoscopy
  • [ISO-abbreviation] Endoscopy
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 3.1.1.3 / Lipase; EC 3.2.1.- / Amylases
  • [Number-of-references] 51
  •  go-up   go-down


26. Keenan DB, Cartaya R, Mastrototaro JJ: The pathway to the closed-loop artificial pancreas: research and commercial perspectives. Pediatr Endocrinol Rev; 2010 Aug;7 Suppl 3:445-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pathway to the closed-loop artificial pancreas: research and commercial perspectives.
  • In addition, artificial pancreas (AP) research has progressed to clinical studies, using combinations of commercially available devices.
  • [MeSH-major] Diabetes Mellitus / drug therapy. Diabetes Mellitus / metabolism. Insulin Infusion Systems. Pancreas, Artificial

  • MedlinePlus Health Information. consumer health - Diabetes.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20877259.001).
  • [ISSN] 1565-4753
  • [Journal-full-title] Pediatric endocrinology reviews : PER
  • [ISO-abbreviation] Pediatr Endocrinol Rev
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Israel
  •  go-up   go-down


27. Kartalis N, Lindholm TL, Aspelin P, Permert J, Albiin N: Diffusion-weighted magnetic resonance imaging of pancreas tumours. Eur Radiol; 2009 Aug;19(8):1981-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffusion-weighted magnetic resonance imaging of pancreas tumours.
  • The purpose of this study was to evaluate the accuracy of diffusion-weighted imaging (DWI) in diagnosis of pancreas cancer, to compare DWI with a conventional comprehensive MRI (MRI-c) and to analyse apparent diffusion coefficient (ADC) values of lesions.
  • Thirty-six patients with pancreatic lesions (12 malignant and 24 benign) and 39 patients without lesions were included.
  • Mean ADC values of malignant lesions were significantly lower than those of benign lesions.
  • DWI has a similar accuracy to MRI-c in diagnosis of pancreas cancer.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging / methods. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur Radiol. 2010 Jul;20(7):1768-9; author reply 1770-1 [20204646.001]
  • [Cites] Radiology. 2003 Oct;229(1):81-90 [14519871.001]
  • [Cites] Acad Radiol. 2007 Jun;14(6):643-50 [17502253.001]
  • [Cites] Acta Radiol. 2007 Jul;48(6):695-703 [17611881.001]
  • [Cites] AJR Am J Roentgenol. 2005 Sep;185(3):700-3 [16120921.001]
  • [Cites] Eur Radiol. 2008 Apr;18(4):723-30 [17929022.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):67-73 [18094295.001]
  • [Cites] AJR Am J Roentgenol. 2006 Jul;187(1):181-4 [16794174.001]
  • [Cites] Eur Radiol. 2007 Jan;17(1):201-4 [16865369.001]
  • [Cites] Gastrointest Endosc. 2003 Jan;57(1):23-9 [12518126.001]
  • [Cites] Pediatr Radiol. 2007 Aug;37(8):749-68 [17589837.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2008 Oct;35(10):1775-85 [18481063.001]
  • [Cites] AJR Am J Roentgenol. 1999 Aug;173(2):393-8 [10430143.001]
  • [Cites] AJR Am J Roentgenol. 2007 Feb;188(2):409-14 [17242249.001]
  • [Cites] Radiology. 1999 Mar;210(3):617-23 [10207458.001]
  • [Cites] Ann Surg Oncol. 2008 Sep;15(9):2465-71 [18551347.001]
  • [Cites] Skeletal Radiol. 2000 Jun;29(6):320-3 [10929413.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] Abdom Imaging. 2007 Jul-Aug;32(4):481-3 [17431713.001]
  • [Cites] Magn Reson Med. 2005 Oct;54(4):878-85 [16155895.001]
  • [Cites] Eur Radiol. 2008 Mar;18(3):486-92 [17994317.001]
  • [Cites] Radiology. 1986 Nov;161(2):401-7 [3763909.001]
  • [Cites] Am J Gastroenterol. 2004 May;99(5):844-50 [15128348.001]
  • [Cites] Acta Radiol. 2008 May;49(4):383-6 [18415779.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Eur Radiol. 2008 Mar;18(3):477-85 [17960390.001]
  • [Cites] Neuroradiology. 1999 Mar;41(3):171-4 [10206159.001]
  • [Cites] J Magn Reson Imaging. 2001 May;13(5):757-60 [11329198.001]
  • [Cites] J Magn Reson Imaging. 2008 Oct;28(4):928-36 [18821618.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):708-10 [12933464.001]
  • (PMID = 19308414.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Su C, Chen X, Zhang ZY, Gu WQ, Zhang MJ, Zhou GW, Li XY, Ning G, Li HW: [Protective effect of heme oxygenase-1 induction in vivo to pancreas islet xenograft]. Zhonghua Wai Ke Za Zhi; 2009 Aug 15;47(16):1249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Protective effect of heme oxygenase-1 induction in vivo to pancreas islet xenograft].
  • OBJECTIVE: To study the protective effect of islet xenograft and its possible mechanism of high expression of heme oxygenase-1 (HO-1) in donor pancreas islet induced by cobalt protoporphyrin (CoPP).
  • [MeSH-major] Heme Oxygenase-1 / metabolism. Pancreas Transplantation

  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19781175.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protoporphyrins; 130068-27-8 / Interleukin-10; 63AAN3JDZE / cobaltiprotoporphyrin; EC 1.14.99.3 / Heme Oxygenase-1
  •  go-up   go-down


29. Grützmann R, Niedergethmann M, Pilarsky C, Klöppel G, Saeger HD: Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment. Oncologist; 2010;15(12):1294-309
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraductal papillary mucinous tumors of the pancreas: biology, diagnosis, and treatment.
  • Pancreatic intraductal papillary mucinous neoplasms (IPMNs) rank among the most common cystic tumors of the pancreas.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / therapy. Humans. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pancreas. 2004 Oct;29(3):212-7 [15367887.001]
  • [Cites] N Engl J Med. 2004 Sep 16;351(12):1218-26 [15371579.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1329-35 [2548703.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] J Gastrointest Surg. 2008 Apr;12(4):645-50 [18097728.001]
  • [Cites] Dig Surg. 2008;25(1):46-51 [18292661.001]
  • [Cites] Oncol Rep. 2008 May;19(5):1185-90 [18425375.001]
  • [Cites] J Gastrointest Surg. 2008 Jun;12(6):1127-32 [18299945.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):474-81 [17680299.001]
  • [Cites] Pancreatology. 2008;8(3):277-84 [18497541.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:10 [18577196.001]
  • [Cites] Arch Surg. 2008 Jul;143(7):639-46; discussion 646 [18645105.001]
  • [Cites] AJR Am J Roentgenol. 2008 Sep;191(3):802-7 [18716113.001]
  • [Cites] World J Surg. 2008 Oct;32(10):2253-60 [18668283.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2737-41 [18843017.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3187-92 [18766406.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Am J Gastroenterol. 2000 Apr;95(4):961-5 [10763945.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):26-42 [11145249.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):942-8 [11420467.001]
  • [Cites] Am J Surg Pathol. 2001 Aug;25(8):1047-53 [11474289.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):62-77 [11815961.001]
  • [Cites] J Pathol. 2002 Jun;197(2):201-10 [12015744.001]
  • [Cites] Gut. 2002 Sep;51(3):446-9 [12171972.001]
  • [Cites] Gastrointest Endosc. 2002 Oct;56(4):543-7 [12297771.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Arch Surg. 2002 Nov;137(11):1274-8 [12413317.001]
  • [Cites] Carcinogenesis. 2003 Feb;24(2):193-8 [12584167.001]
  • [Cites] Cancer. 1992 Sep 15;70(6):1505-13 [1516002.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):980-94 [8712298.001]
  • [Cites] Gut. 1996 Sep;39(3):457-64 [8949654.001]
  • [Cites] World J Surg. 1998 Aug;22(8):874-8 [9673562.001]
  • [Cites] Am J Surg Pathol. 1999 Apr;23(4):410-22 [10199470.001]
  • [Cites] Adv Anat Pathol. 1999 Mar;6(2):65-77 [10331069.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1835-40 [10362809.001]
  • [Cites] J Gastrointest Surg. 2008 Feb;12(2):234-42 [18040749.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3193-8 [18784959.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1499-507 [18820670.001]
  • [Cites] Am J Gastroenterol. 2008 Nov;103(11):2871-7 [18775021.001]
  • [Cites] Gastrointest Endosc. 2009 Feb;69(2 Suppl):S203-9 [19179158.001]
  • [Cites] Pancreas. 2009 Mar;38(2):131-6 [18981954.001]
  • [Cites] Ann Surg. 1999 Aug;230(2):152-61 [10450728.001]
  • [Cites] Arch Surg. 1999 Oct;134(10):1131-6 [10522860.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):144-52 [15654794.001]
  • [Cites] Pathologe. 2005 Feb;26(1):22-30 [15624092.001]
  • [Cites] Am J Surg. 2005 May;189(5):632-6; discussion 637 [15862510.001]
  • [Cites] J Gastroenterol. 2005 May;40(5):518-25 [15942718.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4681-8 [16000561.001]
  • [Cites] Mod Pathol. 2005 Aug;18(8):1034-42 [15832194.001]
  • [Cites] Pancreas. 2005 Nov;31(4):344-9 [16258368.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):800-5 [16021508.001]
  • [Cites] Virchows Arch. 2005 Nov;447(5):794-9 [16088402.001]
  • [Cites] Ann Surg. 2005 Dec;242(6):774-8, discussion 778-80 [16327487.001]
  • [Cites] World J Surg. 2005 Dec;29(12):1650-7 [16311856.001]
  • [Cites] Radiology. 2006 Feb;238(2):560-9 [16436817.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):582-94 [16523362.001]
  • [Cites] Surg Oncol. 2005 Dec;14(4):155-78 [16517154.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):320-5 [16333711.001]
  • [Cites] Cancer. 2006 Jun 25;108(3):163-73 [16550572.001]
  • [Cites] Ann Surg Oncol. 2006 Jul;13(7):955-60 [16788757.001]
  • [Cites] Virchows Arch. 2006 Jul;449(1):112-6 [16639605.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2006;13(4):280-5 [16858538.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1067-76 [16931950.001]
  • [Cites] J Pathol. 2006 Sep;210(1):42-8 [16794990.001]
  • [Cites] Ann Surg. 2006 Oct;244(4):572-82 [16998366.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1561-9 [17122512.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2567-75 [17054109.001]
  • [Cites] Pancreatology. 2006;6(6):626-34 [17135772.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):229-43 [17349581.001]
  • [Cites] JOP. 2007;8(2):206-13 [17356245.001]
  • [Cites] Cancer Lett. 2007 May 8;249(2):242-8 [17097223.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Apr;5(4):489-95 [17350894.001]
  • [Cites] J Gastrointest Surg. 2007 Mar;11(3):338-44 [17458608.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2007;14(3):243-54 [17520199.001]
  • [Cites] Gut. 2007 Aug;56(8):1086-90 [17127707.001]
  • [Cites] Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10 [17631133.001]
  • [Cites] Cancer Cell. 2007 Sep;12(3):266-79 [17785207.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):199-205 [17909912.001]
  • [Cites] J Gastrointest Surg. 2008 Jan;12(1):101-9 [17917784.001]
  • [Cites] World J Surg. 2008 Feb;32(2):271-8; discussion 279-80 [18027021.001]
  • [Cites] Ann Surg. 2009 Mar;249(3):440-7 [19247032.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2009;23(1):35-48 [19258185.001]
  • [Cites] Cancer Biol Ther. 2009 Feb;8(4):340-6 [19106647.001]
  • [Cites] Mol Biol Cell. 2009 Apr;20(7):1992-2003 [19225151.001]
  • [Cites] Pancreatology. 2009;9(1-2):34-44 [19077453.001]
  • [Cites] Am J Gastroenterol. 2009 Sep;104(9):2175-81 [19491823.001]
  • [Cites] Radiology. 2009 Oct;253(1):106-15 [19703865.001]
  • [Cites] Pancreatology. 2009;9(5):631-8 [19657218.001]
  • [Cites] Gastroenterology. 2010 Feb;138(2):531-40 [19818780.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):477-82 [20142730.001]
  • [Cites] Ann Surg. 2010 Mar;251(3):470-6 [20142731.001]
  • [Cites] Ann Surg Oncol. 2010 Apr;17(4):1168-76 [19936839.001]
  • [Cites] Pancreas. 2010 Apr;39(3):308-14 [19924021.001]
  • [Cites] Gastrointest Endosc. 2003 Jul;58(1):59-64 [12838222.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Langenbecks Arch Surg. 2003 Dec;388(6):392-400 [12910422.001]
  • [Cites] Ann Surg. 2004 Mar;239(3):400-8 [15075659.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):839-48 [15223952.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Jul;2(7):606-21 [15224285.001]
  • [Cites] Am J Surg Pathol. 2004 Aug;28(8):977-87 [15252303.001]
  • [Cites] Virchows Arch. 2004 Aug;445(2):168-78 [15185076.001]
  • (PMID = 21147870.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3227924
  •  go-up   go-down


30. Li WC: In vitro transdifferentiation of human hepatoma cells into pancreatic-like cells. Methods Mol Biol; 2009;560:99-110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro transdifferentiation of human hepatoma cells into pancreatic-like cells.
  • Transdifferentiation from different cellular origins into pancreatic-like beta-cells is of clinical significance since this approach may offer a potential cure for diabetes.
  • In order to achieve this goal, the liver is considered as a suitable candidate due to its close developmental relationship to the pancreas, its large size and a well-documented regenerative capacity that could provide enough original tissues to initiate the transdifferentiation procedure.
  • In this chapter, we describe a protocol to overexpress Pdx1, a master regulator essential for pancreas development in the cultured human liver cell line, HepG2.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Cell Differentiation. Cytological Techniques. Liver Neoplasms / pathology. Pancreas / cytology
  • [MeSH-minor] Cell Line, Tumor. Cell Transdifferentiation. Humans. Insulin-Secreting Cells / cytology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19504247.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Kawakami T, Saeki K, Takeyama N, Wu G, Sakudo A, Matsumoto Y, Hayashi T, Onodera T: Detection of proteolytic cleavages of diabetes-associated protein IA-2 beta in the pancreas and the brain using novel anti-IA-2 beta monoclonal antibodies. Int J Mol Med; 2007 Aug;20(2):177-85
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of proteolytic cleavages of diabetes-associated protein IA-2 beta in the pancreas and the brain using novel anti-IA-2 beta monoclonal antibodies.
  • IA-2 beta exists mainly in a 60-kDa form, and is frequently located in the dense-core secretory vesicles of pancreatic beta cells.
  • In the present study, we characterized the major forms of IA-2 beta in the brain and pancreas of normal and non-obese diabetic (NOD) mice.
  • On the contrary, only the 60-kDa isoform of IA-2 beta was expressed in the mouse pancreas and in the mouse pancreatic beta cell line, MIN6.
  • Furthermore, Western blotting and immunohistochemistry demonstrated that NOD mice expressed similar isoforms present in the brains and pancreatic islets of C57BL/6J, BALC/CA and ICR mice, accordingly.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Autoantigens / analysis. Autoantigens / immunology. Autoantigens / metabolism. Brain / metabolism. Membrane Proteins / analysis. Membrane Proteins / immunology. Membrane Proteins / metabolism. Pancreas / metabolism. Protein Tyrosine Phosphatases / analysis. Protein Tyrosine Phosphatases / immunology. Protein Tyrosine Phosphatases / metabolism
  • [MeSH-minor] Amino Acid Sequence. Animals. Diabetes Mellitus, Type 1 / enzymology. Isoenzymes / metabolism. Mice. Mice, Inbred BALB C. Mice, Inbred C57BL. Mice, Inbred ICR. Mice, Inbred NOD. Mice, Nude. Mice, Transgenic. Molecular Sequence Data. Peptide Fragments / analysis. Protein Processing, Post-Translational. Protein Tyrosine Phosphatase, Non-Receptor Type 1. Receptor-Like Protein Tyrosine Phosphatases, Class 8. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611635.001).
  • [ISSN] 1107-3756
  • [Journal-full-title] International journal of molecular medicine
  • [ISO-abbreviation] Int. J. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Autoantigens; 0 / Isoenzymes; 0 / Membrane Proteins; 0 / Peptide Fragments; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 1; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / Ptprn protein, mouse; EC 3.1.3.48 / Receptor-Like Protein Tyrosine Phosphatases, Class 8
  •  go-up   go-down


32. Adams AL, Siegal GP, Jhala NC: Solid pseudopapillary tumor of the pancreas: a review of salient clinical and pathologic features. Adv Anat Pathol; 2008 Jan;15(1):39-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid pseudopapillary tumor of the pancreas: a review of salient clinical and pathologic features.
  • Solid pseudopapillary tumor (SPT) of the pancreas is a rare tumor of uncertain histogenesis characterized, as the name suggests, by a cystic and solid pattern of growth with formation of pseudopapillae.
  • Accounting for only a small percentage of pancreatic neoplasms, SPT occurs primarily in young women, although cases in older patients and men have been reported.
  • The tumor is thought to have low-grade malignant potential, as the majority of the cases are cured by simple but complete surgical resection.
  • Knowledge of the unique morphologic and demographic characteristics of this neoplasm is essential for accurate diagnosis.
  • Herein, we review the clinical and pathologic features, which can help separate SPTs from other primary pancreatic tumors.
  • [MeSH-major] Carcinoma, Papillary / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunophenotyping. Pancreatic Cyst / diagnosis. Pancreatic Cyst / immunology. Pancreatic Cyst / pathology. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156811.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


33. Kung JW, Brown A, Kruskal JB, Goldsmith JD, Pedrosa I: Heterotopic pancreas: typical and atypical imaging findings. Clin Radiol; 2010 May;65(5):403-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterotopic pancreas: typical and atypical imaging findings.
  • Heterotopic pancreas is a common condition often encountered during laporotomy or autopsy.
  • Prospective radiographic diagnosis is challenging because of the variable imaging appearances.
  • The purpose of this review is to present the typical and atypical appearances of heterotopic pancreas on imaging studies.
  • [MeSH-major] Choristoma / diagnosis. Gastrointestinal Diseases / diagnosis. Pancreas
  • [MeSH-minor] Adolescent. Adult. Biomarkers / blood. Diagnosis, Differential. Endosonography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20380941.001).
  • [ISSN] 1365-229X
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers
  • [Number-of-references] 25
  •  go-up   go-down


34. Dubova EA, Shchegolev AI: [Clinical and morphological characteristics of intraductal papillary mucinous tumors of the pancreas]. Arkh Patol; 2009 Mar-Apr;71(2):9-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and morphological characteristics of intraductal papillary mucinous tumors of the pancreas].
  • The paper presents the results of a comprehensive morphological study of the surgical material from 5 patients (males aged 49 to 69 years) with intraductal papillary mucinous tumors (IDPMT) of the pancreas.
  • The pancreatobiliary type of IDPMT was established in 4 cases (one adenoma from the peripheral branches of the pancreatic duct, one IDPMT with the borderline malignancy potential from the major pancreatic duct, and two intraductal papillary mucinous carcinomas from the major pancreatic duct).
  • One patient was diagnosed as having an enteric type of a tumor (IDPMT with the borderline malignancy from the major pancreatic duct), which was characterized by the expression in the MUC2 and MUC5AC cells and by that of cytokeratin 20.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adenoma / metabolism. Adenoma / pathology. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / pathology
  • [MeSH-minor] Aged. Gene Expression Regulation, Neoplastic. Humans. Keratins / biosynthesis. Male. Middle Aged. Mucin 5AC / biosynthesis. Mucin-1 / biosynthesis. Neoplasm Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19507570.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / MUC1 protein, human; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucin-1; 0 / Neoplasm Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


35. Xu J, Liang Z, Hao S, Zhu L, Ashish M, Jin C, Fu D, Ni Q: Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging. Abdom Imaging; 2009 Nov;34(6):759-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma: dynamic 64-slice helical CT with perfusion imaging.
  • Thus, in lesions of the tissues of the pancreas, this offers to increase the accuracy of CT diagnosis.
  • In this study, our aim was to explore the perfusion characteristics of normal pancreas and pancreatic adenocarcinoma.
  • METHODS: Dynamic 64-slice helical CT was conducted in 36 patients with non-pancreatic disease and in 40 patients with histopathologically proven pancreatic adenocarcinoma.
  • RESULTS: There was no significant difference noted between the distribution of BF, BV, and PS values in different regions of the pancreas, namely the head, neck, body, and tail (P > 0.05).
  • The BF, BV, and PS of normal pancreas were recorded as 135.24 +/- 48.36 ml min(-1) 100 g(-1), 200.55 +/- 54.96 ml 100 g(-1), and 49.75 +/- 24.27 ml min(-1) 100 g(-1), respectively.
  • BF, BV, and PS values of the tumor tissue of pancreatic adenocarcinoma decreased significantly compared to normal pancreas (P < 0.05).
  • CONCLUSIONS: Normal pancreas appears homogenous on perfusion CT.
  • A significant decrease of BF, BV, and PS was observed in pancreatic adenocarcinoma.
  • Dynamic 64-slice helical CT with perfusion imaging should be considered a potential modality to increase the accuracy of CT diagnosis for pancreatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / radiography. Pancreatic Neoplasms / radiography. Tomography, Spiral Computed / methods
  • [MeSH-minor] Case-Control Studies. Contrast Media. Female. Humans. Iohexol. Male. Middle Aged. Pancreas / blood supply. Pancreas / radiography. Pancreaticoduodenectomy. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672566.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol
  •  go-up   go-down


36. Puglisi MA, Giuliani L, Fierabracci A: Identification and characterization of a novel expandable adult stem/progenitor cell population in the human exocrine pancreas. J Endocrinol Invest; 2008 Jun;31(6):563-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and characterization of a novel expandable adult stem/progenitor cell population in the human exocrine pancreas.
  • In particular, the existence of pancreatic stem cells remains elusive because specific markers for their identification are not available.
  • We established a method for the isolation of a population of stem/progenitor cells from the human exocrine pancreas, and propose it as a model for other human compact organs.
  • We identified a novel predominant functional type of stem/progenitor cell within the human exocrine pancreas, able to generate insulin-producing cells and potentially non-pancreatic cells.
  • [MeSH-major] Cell Proliferation. Pancreas, Exocrine / cytology. Stem Cells / cytology
  • [MeSH-minor] Adult. Cell Differentiation / physiology. Cell Line, Tumor. Cells, Cultured. Coculture Techniques / methods. Humans

  • MedlinePlus Health Information. consumer health - Stem Cells.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endocrinology. 2002 Aug;143(8):3152-61 [12130581.001]
  • [Cites] Stem Cells Dev. 2007 Feb;16(1):75-89 [17348806.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):7999-8004 [10884429.001]
  • [Cites] Science. 2003 Jan 17;299(5605):363 [12532008.001]
  • [Cites] Nat Rev Genet. 2004 Nov;5(11):873-8 [15520797.001]
  • [Cites] Thyroid. 2002 Apr;12(4):281-6 [12034051.001]
  • [Cites] Adv Exp Med Biol. 1992;321:85-9; discussion 91-3 [1449085.001]
  • [Cites] Pancreas. 2005 Aug;31(2):108-18 [16024996.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(5-6):973-84 [16431150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10733-8 [11535818.001]
  • [Cites] Diabetes Metab Res Rev. 2004 Jan-Feb;20(1):13-27 [14737742.001]
  • [Cites] Diabetes. 1993 Dec;42(12):1715-20 [8243817.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Mar 5;99(5):3024-9 [11867737.001]
  • [Cites] Nat Med. 2006 Mar;12 (3):310-6 [16491084.001]
  • [Cites] Lancet. 2004 Nov 20-26;364(9448):1872-83 [15555667.001]
  • [Cites] FEBS Lett. 2000 Jun 9;475(1):17-21 [10854849.001]
  • [Cites] Cell. 2000 Jan 7;100(1):157-68 [10647940.001]
  • [Cites] Nature. 2000 Oct 26;407(6807):963-70 [11069169.001]
  • [Cites] Science. 2004 Dec 24;306(5705):2261-4 [15564314.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1499-507 [15185290.001]
  • [Cites] BMJ. 2002 Aug 17;325(7360):372-6 [12183311.001]
  • [Cites] J Neurosci. 1996 Feb 1;16(3):1091-100 [8558238.001]
  • [Cites] Diabetes. 1997 Jul;46(7):1120-3 [9200645.001]
  • [Cites] Diabetologia. 2006 Oct;49(10):2359-67 [16896938.001]
  • [Cites] J Endocrinol. 2004 Jul;182(1):113-22 [15225136.001]
  • [Cites] Cell. 2001 Jun 29;105(7):829-41 [11439179.001]
  • [Cites] Nature. 2004 May 6;429(6987):41-6 [15129273.001]
  • [Cites] J Cell Mol Med. 2005 Apr-Jun;9(2):331-44 [15963253.001]
  • [Cites] Pancreas. 1992;7(3):320-5 [1375749.001]
  • [Cites] Circ Res. 2004 Oct 29;95(9):911-21 [15472116.001]
  • [Cites] Diabetes. 2001 Mar;50(3):521-33 [11246871.001]
  • [Cites] Lab Invest. 2006 Feb;86(2):141-53 [16402034.001]
  • [Cites] Nature. 2003 Apr 17;422(6933):688-94 [12700753.001]
  • [Cites] N Engl J Med. 2003 Aug 7;349(6):570-82 [12904523.001]
  • [Cites] Methods Mol Biol. 2006;333:47-104 [16790847.001]
  • [Cites] Endocrinology. 2001 Nov;142(11):4956-68 [11606464.001]
  • [Cites] Pediatr Surg Int. 2007 Sep;23(9):837-9 [17619197.001]
  • [Cites] Circ Res. 2003 Apr 4;92(6):598-608 [12676811.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jun 21;294(4):906-11 [12061793.001]
  • [Cites] J Pathol. 2002 Jul;197(4):430-40 [12115860.001]
  • [Cites] JOP. 2003 Jul;4(4):137-45 [12853681.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Apr 16;316(4):1094-100 [15044097.001]
  • [Cites] Immunol Cell Biol. 1999 Dec;77(6):509-15 [10571671.001]
  • [Cites] Biochem Biophys Res Commun. 2002 May 3;293(2):670-4 [12054520.001]
  • [Cites] Cell. 2004 Mar 5;116(5):639-48 [15006347.001]
  • (PMID = 18591892.001).
  • [ISSN] 1720-8386
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


37. Tajima Y, Kuroki T, Tsutsumi R, Fukuda K, Kitasato A, Adachi T, Mishima T, Kanematsu T: Risk factors for pancreatic anastomotic leakage: the significance of preoperative dynamic magnetic resonance imaging of the pancreas as a predictor of leakage. J Am Coll Surg; 2006 May;202(5):723-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for pancreatic anastomotic leakage: the significance of preoperative dynamic magnetic resonance imaging of the pancreas as a predictor of leakage.
  • BACKGROUND: The histologic degree of pancreatic fibrosis can be assessed preoperatively by using the time-signal intensity curve (TIC) of the pancreas obtained from dynamic magnetic resonance imaging.
  • STUDY DESIGN: To identify risk factors for postoperative pancreatic anastomotic leakage and to assess the impact of pancreatic TIC on this complication, 89 patients who underwent a pancreatic head resection with an end-to-side pancreaticojejunostomy between December 1998 and August 2005 were retrospectively reviewed.
  • The pancreatic TIC profiles were classified into 3 types: type I, indicating a normal pancreas without fibrosis; and types II and III indicating fibrotic pancreas.
  • In a univariate analysis, pancreatic texture (hard, 3% versus intermediate, 20% versus soft, 23%; p = 0.046), pancreatic duct size (> 3 mm, 8% versus <or= 3 mm, 25%; p = 0.037), and pancreatic TIC (types II, III, 3% versus type I, 25%; p = 0.006) were notably associated with pancreatic anastomotic leakage.
  • In a multivariable analysis, pancreatic TIC (odds ratio [OR], 9.58; 95% CI, 1.1 to 91.7) was the only marked independent predictor of postoperative pancreatic leakage.
  • A subanalysis of 52 patients with type I pancreatic TIC demonstrated hemoglobin A1c (odds ratio, 9.81; 95% CI, 1.2 to 127.9) to be a notable predictor of leakage and pancreatic leakage developed in diabetic patients with a high hemoglobin A1c concentration (> 6.0%) than in those with a normal hemoglobin A1c level.
  • CONCLUSIONS: Pancreatic TIC from dynamic MRI provides reliable information for predicting risk of pancreatic anastomotic leakage after pancreatic head resection.
  • Especially in patients with type I pancreatic TIC, the presence of uncontrolled diabetes is considered a primary risk factor for postoperative pancreatic leakage.
  • [MeSH-major] Anastomosis, Surgical / adverse effects. Magnetic Resonance Imaging. Pancreatic Diseases / surgery. Pancreaticojejunostomy. Postoperative Complications / diagnosis

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648011.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


38. Hoffman BG, Zavaglia B, Witzsche J, Ruiz de Algara T, Beach M, Hoodless PA, Jones SJ, Marra MA, Helgason CD: Identification of transcripts with enriched expression in the developing and adult pancreas. Genome Biol; 2008;9(6):R99
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of transcripts with enriched expression in the developing and adult pancreas.
  • BACKGROUND: Despite recent advances, the transcriptional hierarchy driving pancreas organogenesis remains largely unknown, in part due to the paucity of comprehensive analyses.
  • To address this deficit we generated ten SAGE libraries from the developing murine pancreas spanning Theiler stages 17-26, making use of available Pdx1 enhanced green fluorescent protein (EGFP) and Neurog3 EGFP reporter strains, as well as tissue from adult islets and ducts.
  • RESULTS: We used a specificity metric to identify 2,536 tags with pancreas-enriched expression compared to 195 other mouse SAGE libraries.
  • We subsequently grouped co-expressed transcripts with differential expression during pancreas development using K-means clustering.
  • We validated the clusters first using quantitative real time PCR and then by analyzing the Theiler stage 22 pancreas in situ hybridization staining patterns of over 600 of the identified genes using the GenePaint database.
  • These were then categorized into one of the five expression domains within the developing pancreas.
  • Based on these results we identified a cascade of transcriptional regulators expressed in the endocrine pancreas lineage and, from this, we developed a predictive regulatory network describing beta-cell development.
  • CONCLUSION: Taken together, this work provides evidence that the SAGE libraries generated here are a valuable resource for continuing to elucidate the molecular mechanisms regulating pancreas development.
  • Furthermore, our studies provide a comprehensive analysis of pancreas development, and insights into the regulatory networks driving this process are revealed.
  • [MeSH-major] Gene Expression Profiling. Pancreas / embryology

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Novartis Found Symp. 2007;281:2-18; discussion 18-24, 50-3, 208-9 [17534062.001]
  • [Cites] Development. 2000 Apr;127(8):1563-72 [10725233.001]
  • [Cites] J Neurosci. 1999 Dec 1;19(23):10348-56 [10575032.001]
  • [Cites] Curr Opin Cell Biol. 1999 Dec;11(6):663-8 [10600706.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):36-44 [10615124.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 15;97(4):1607-11 [10677506.001]
  • [Cites] Development. 2002 May;129(10):2447-57 [11973276.001]
  • [Cites] Diabetes. 2002 Jul;51(7):1997-2004 [12086925.001]
  • [Cites] Nat Rev Genet. 2002 Jul;3(7):524-32 [12094230.001]
  • [Cites] Diabetes. 2008 Mar;57(3):654-68 [18071024.001]
  • [Cites] BMC Genomics. 2007;8:127 [17519037.001]
  • [Cites] Cell. 2002 Jul 26;110(2):251-60 [12150932.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):128-34 [12185368.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Diabetes Metab Res Rev. 2003 Jan-Feb;19(1):32-42 [12592642.001]
  • [Cites] Biotechniques. 2003 Feb;34(2):374-8 [12613259.001]
  • [Cites] Dev Cell. 2003 Mar;4(3):383-93 [12636919.001]
  • [Cites] J Biol Chem. 2003 May 9;278(19):17130-40 [12604598.001]
  • [Cites] Diabetes Metab Res Rev. 2003 May-Jun;19(3):191-201 [12789652.001]
  • [Cites] Diabetes. 2003 Jul;52(7):1604-10 [12829622.001]
  • [Cites] Dev Cell. 2007 Jul;13(1):103-14 [17609113.001]
  • [Cites] PLoS Genet. 2007 Oct;3(10):1867-83 [17953485.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4445-54 [10825208.001]
  • [Cites] Endocrinology. 2000 Jun;141(6):1926-9 [10830272.001]
  • [Cites] Mech Dev. 2000 Jun;94(1-2):199-203 [10842072.001]
  • [Cites] Diabetes. 2000 Feb;49(2):163-76 [10868931.001]
  • [Cites] Hum Mol Genet. 2001 Mar 15;10(6):617-27 [11230181.001]
  • [Cites] J Biol Chem. 2001 Jun 29;276(26):24059-67 [11306577.001]
  • [Cites] Science. 2001 Oct 19;294(5542):564-7 [11577200.001]
  • [Cites] Differentiation. 2001 Oct;68(4-5):205-19 [11776473.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3488-96 [11971979.001]
  • [Cites] Genome Biol. 2003;4(10):R70 [14519205.001]
  • [Cites] Development. 2004 Jan;131(1):165-79 [14660441.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D552-6 [14681479.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Mar;36(3):365-71 [14687913.001]
  • [Cites] Dev Dyn. 2004 Jan;229(1):176-200 [14699589.001]
  • [Cites] Development. 2004 Feb;131(4):807-17 [14736742.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(7):2757-66 [15024065.001]
  • [Cites] Dev Biol. 2004 Apr 1;268(1):174-84 [15031114.001]
  • [Cites] Cell. 2004 Apr 16;117(2):185-98 [15084257.001]
  • [Cites] J Biol Chem. 2004 May 7;279(19):19407-20 [14976186.001]
  • [Cites] Genome Biol. 2004;5(7):R51 [15239836.001]
  • [Cites] Development. 2004 Aug;131(16):3931-42 [15253934.001]
  • [Cites] Diabetologia. 2004 Apr;47(4):597-613 [15298336.001]
  • [Cites] PLoS Biol. 2004 Sep;2(9):E247 [15226823.001]
  • [Cites] Genomics. 2004 Oct;84(4):631-6 [15475240.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1191-202 [8980226.001]
  • [Cites] Mol Cell Biol. 1997 Oct;17(10):5679-87 [9315626.001]
  • [Cites] Genome Res. 1997 Oct;7(10):986-95 [9331369.001]
  • [Cites] Development. 1997 Nov;124(21):4243-52 [9334273.001]
  • [Cites] J Biol Chem. 1998 Feb 27;273(9):5366-74 [9478997.001]
  • [Cites] Genome Res. 1998 Mar;8(3):186-94 [9521922.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1705-13 [9620856.001]
  • [Cites] Diabetes. 1998 Dec;47(12):1817-23 [9836511.001]
  • [Cites] J Biol Chem. 1999 Jan 29;274(5):2665-71 [9915796.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):877-81 [10476967.001]
  • [Cites] Nucleic Acids Res. 2005;33(1):66-80 [15640446.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1025-34 [15604203.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1808-17 [15618358.001]
  • [Cites] Nat Genet. 2005 Apr;37(4):382-90 [15778709.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):4972-7 [15749820.001]
  • [Cites] Genome Biol. 2005;6(4):R33 [15833120.001]
  • [Cites] Dev Biol. 2005 Jul 1;283(1):1-16 [15907831.001]
  • [Cites] Nucleic Acids Res. 2005 Jul 1;33(Web Server issue):W741-8 [15980575.001]
  • [Cites] Nat Rev Genet. 2005 Dec;6(12):893-904 [16341070.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18485-90 [16352711.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D68-73 [16381958.001]
  • [Cites] Endocrinology. 2006 Apr;147(4):1950-8 [16373422.001]
  • [Cites] BMC Bioinformatics. 2006;7:116 [16524483.001]
  • [Cites] Development. 2006 May;133(10):1955-66 [16651540.001]
  • [Cites] Genomics. 2006 Aug;88(2):133-42 [16698233.001]
  • [Cites] Genome Res. 2007 Jan;17(1):108-16 [17135571.001]
  • [Cites] Genome Biol. 2007;8(1):R6 [17210078.001]
  • (PMID = 18554416.001).
  • [ISSN] 1474-760X
  • [Journal-full-title] Genome biology
  • [ISO-abbreviation] Genome Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / enhanced green fluorescent protein; 147336-22-9 / Green Fluorescent Proteins
  • [Other-IDs] NLM/ PMC2481431
  •  go-up   go-down


39. Saif MW, Oettle H, Vervenne WL, Thomas JP, Spitzer G, Visseren-Grul C, Enas N, Richards DA: Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas. Cancer J; 2009 Jul-Aug;15(4):339-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized double-blind phase II trial comparing gemcitabine plus LY293111 versus gemcitabine plus placebo in advanced adenocarcinoma of the pancreas.
  • BACKGROUND: LY293111 (LY) is a novel oral anticancer agent with leukotriene B4 receptor antagonist and peroxisome proliferator-activated receptor gamma agonist properties, producing promising results alone and in combination with gemcitabine in pancreatic cancer xenograft models.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas were randomly assigned to gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and continuously administered LY 600 mg twice daily or gemcitabine 1000 mg/m on days 1, 8, and 15 of a 28-day cycle and daily oral placebo.
  • CONCLUSIONS: These results do not demonstrate any benefit to adding LY to gemcitabine in unpretreated patients with advanced pancreatic carcinoma.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Benzoates / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19672152.001).
  • [ISSN] 1528-9117
  • [Journal-full-title] Cancer journal (Sudbury, Mass.)
  • [ISO-abbreviation] Cancer J
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Benzoates; 0 / LY 293111; 0 / Receptors, Leukotriene B4; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


40. Kayacetin E, Yol S, Kayacetin S: Giant aneurysm of the splenic artery adherent to the pancreas with splenic infarct: report of a case. Acta Chir Belg; 2006 May-Jun;106(3):348-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant aneurysm of the splenic artery adherent to the pancreas with splenic infarct: report of a case.
  • We present a case of a 9 cm giant splenic artery aneurysm tightly adherent to the pancreas which was treated surgically.
  • [MeSH-major] Aneurysm / diagnosis. Splenic Artery / surgery. Splenic Infarction / diagnosis

  • MedlinePlus Health Information. consumer health - Aneurysms.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16910011.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


41. Patel VG, Eltayeb OM, Zakaria M, Fortson JK, Weaver WL: Spontaneous subcapsular splenic hematoma: a rare complication of pancreatitis. Am Surg; 2005 Dec;71(12):1066-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subcapsular hematoma of the spleen is a rare complication of pancreatitis despite its close proximity to the pancreas.
  • Pancreatic pseudocyst involving the tail of the pancreas may erode into the splenic hilum causing hilar vessel bleeding with subcapsular dissection and hematoma formation.
  • [MeSH-major] Gastrointestinal Hemorrhage / diagnosis. Hematoma / diagnosis. Pancreatic Pseudocyst / diagnosis. Pancreatitis / diagnosis. Splenic Rupture / diagnosis
  • [MeSH-minor] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Adult. Follow-Up Studies. Hemodynamics / physiology. Humans. Magnetic Resonance Imaging. Male. Remission, Spontaneous. Risk Assessment. Tomography, X-Ray Computed. Ultrasonography, Doppler


42. Meuth-Metzinger VL, Philouze-Rome V, Metzinger L, Gespach C, Guilloteau P: Differential activation of adenylate cyclase by secretin and VIP receptors in the calf pancreas. Pancreas; 2005 Aug;31(2):174-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential activation of adenylate cyclase by secretin and VIP receptors in the calf pancreas.
  • OBJECTIVE: Secretin is a key regulator of pancreatic secretion, but the molecular basis of its action is not well understood, especially in the calf pancreas.
  • Our study investigated the expression and functional competence of secretin receptors (SEC-R) in calf pancreatic membranes.
  • RESULTS: We successfully amplified, by reverse transcriptase-polymerase chain reaction, a fragment of the SEC-R gene from 119-day-old calf pancreas.
  • Accordingly, secretin stimulates AC activity in calf pancreatic membranes isolated from 28- and 119-day-old animals with a potency (Ka) of 1.9 to 2.7 nmol/L.
  • CONCLUSION: Our data indicate that secretin exerts a direct action on pancreatic secretion through specific SEC-R coupled to the AC system.
  • Calf pancreatic SEC-Rs are coexpressed with VIP-2 receptors that we previously identified by ligand binding and cross-linking experiments.
  • [MeSH-major] Adenylyl Cyclases / metabolism. Pancreas / metabolism. Receptors, G-Protein-Coupled / genetics. Receptors, Gastrointestinal Hormone / genetics. Receptors, Vasoactive Intestinal Peptide, Type II / metabolism. Receptors, Vasoactive Intestinal Polypeptide, Type I / metabolism. Secretin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16025005.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AF118556
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Pituitary Adenylate Cyclase-Activating Polypeptide; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Gastrointestinal Hormone; 0 / Receptors, Vasoactive Intestinal Peptide, Type II; 0 / Receptors, Vasoactive Intestinal Polypeptide, Type I; 0 / secretin receptor; 1393-25-5 / Secretin; 37221-79-7 / Vasoactive Intestinal Peptide; EC 4.6.1.1 / Adenylyl Cyclases
  •  go-up   go-down


43. Newman SJ, Steiner JM, Woosley K, Williams DA, Barton L: Histologic assessment and grading of the exocrine pancreas in the dog. J Vet Diagn Invest; 2006 Jan;18(1):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologic assessment and grading of the exocrine pancreas in the dog.
  • Histologic grading schemes for canine inflammatory conditions are sparse, and in the case of the canine pancreas, have not been previously described.
  • In a previous study, we determined that histologic lesions of the exocrine pancreas occurred much more frequently than gross lesions.
  • The intention of the current study was to develop a histologic grading scheme for nonneoplastic lesions following extensive assessment of the exocrine pancreas from dogs presented for necropsy examination.
  • The parameters of the proposed scheme include neutrophilic inflammation, lymphocytic inflammation, pancreatic necrosis, pancreatic fat necrosis, edema, fibrosis, atrophy, and hyperplastic nodules.
  • In this case series, the most common lesion was pancreatic hyperplastic nodules (80.2%), followed by lymphocytic inflammation (52.5%), fibrosis (49.5%), atrophy (46.5%), neutrophilic inflammation (31.7%), pancreatic fat necrosis (25.7%), pancreatic necrosis (16.8%), and edema (9.9%).
  • Neutrophilic inflammation, when present, was often associated with necrosis (pancreatic necrosis, pancreatic fat necrosis, or both) and occasionally with hyperplastic nodules.
  • The utilization of a grading scheme for exocrine pancreatic lesions will be useful in advancing the classification of exocrine pancreatic disease in the dog, which may lead to multicenter studies of exocrine pancreatic disorders in the dog and in other species.
  • [MeSH-major] Dog Diseases / pathology. Pancreas, Exocrine / pathology. Pancreatitis / veterinary

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566269.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


44. Bindi ML, Biancofiore G, Meacci L, Bellissima G, Nardi S, Pieri M, Vistoli F, Boggi U, Sansevero A, Mosca F: Early morbidity after pancreas transplantation. Transpl Int; 2005 Dec;18(12):1356-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early morbidity after pancreas transplantation.
  • This study aims to evaluate and compare the early outcome of both pancreas-alone transplantation (PTA) and simultaneous kidney-pancreas transplantation (SPKT) focusing on the complications affecting the first month after the procedures.
  • [MeSH-major] Kidney Transplantation / adverse effects. Kidney Transplantation / methods. Pancreas Transplantation / adverse effects. Pancreas Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16297054.001).
  • [ISSN] 0934-0874
  • [Journal-full-title] Transplant international : official journal of the European Society for Organ Transplantation
  • [ISO-abbreviation] Transpl. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Immunosuppressive Agents; 0 / Insulin
  •  go-up   go-down


45. Pekary AE, Stevens SA, Sattin A: Valproate and copper accelerate TRH-like peptide synthesis in male rat pancreas and reproductive tissues. Peptides; 2006 Nov;27(11):2901-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Valproate and copper accelerate TRH-like peptide synthesis in male rat pancreas and reproductive tissues.
  • Because high levels of TRH-like peptides occur in the pancreas and pGlu-Glu-Pro-NH(2) (Glu-TRH) has been shown to be a fertilization promoting peptide, we hypothesized that these peptides mediate some of the metabolic and reproductive side effects of Valp.
  • AC, CHR and WD treatments significantly altered TRH and/or TRH-like peptide levels in pancreas and reproductive tissues.
  • Phe-TRH, the most abundant TRH-like peptide in the pancreas, increased 4-fold with AC Valp.
  • Copper (500 microM) increased the in vitro C-terminal amidation of TRH-like peptides by 8- and 4-fold during 24 degrees C incubation of homogenates of pancreas and testis, respectively.
  • Valp (7 microM) accelerated 3-fold the processing of TRH and TRH-like peptide precursors in pancreatic LDCV's incubated at 24 degrees C.
  • [MeSH-major] Copper / pharmacology. Genitalia, Male / drug effects. Pancreas / drug effects. Peptides / metabolism. Thyrotropin-Releasing Hormone / metabolism. Valproic Acid / pharmacology

  • Hazardous Substances Data Bank. COPPER, ELEMENTAL .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945452.001).
  • [ISSN] 0196-9781
  • [Journal-full-title] Peptides
  • [ISO-abbreviation] Peptides
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Peptides; 5Y5F15120W / Thyrotropin-Releasing Hormone; 614OI1Z5WI / Valproic Acid; 789U1901C5 / Copper
  •  go-up   go-down


46. Ablorsu E, Ghazanfar A, Mehra S, Campbell B, Riad H, Pararajasingam R, Parrott N, Picton M, Augustine T, Tavakoli A: Outcome of pancreas transplantation in recipients older than 50 years: a single-centre experience. Transplantation; 2008 Dec 15;86(11):1511-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of pancreas transplantation in recipients older than 50 years: a single-centre experience.
  • BACKGROUND: Pancreas transplantation (PT) remains the only treatment that can restore insulin independence among insulin-dependent diabetics.
  • So, as the incidence of other surgical complication in the more than or equal to 50 group compared with less than 50 (graft thrombosis 13% vs. 11.5%; bleeding 19% vs. 6.7%; abdominal abscess 23% vs. 19%; pancreatic leak 13% vs. 9.6%).
  • One-year patient survival was 88% in more than or equal to 50 vs. 92% in less than 50 group, P=0.399; and pancreas graft survival rate was similar (79% in the >or=50 and 74% in <50, P=0.399).
  • [MeSH-major] Pancreas Transplantation / methods

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19077882.001).
  • [ISSN] 1534-6080
  • [Journal-full-title] Transplantation
  • [ISO-abbreviation] Transplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Dixit R, Sharma S, Dave L: Massive haemothorax in asymptomatic pseudocyst pancreas. Lung India; 2008 Jul;25(3):126-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive haemothorax in asymptomatic pseudocyst pancreas.
  • The case of a 35-year old man who presented with massive left sided haemothorax as a complication of an asymtomatic pancreatic pseudocyst is descibed.
  • The diagnosis was confirmed by very high amylase content of the pleural fluid.
  • The complications of pancreatitis and pancreatic pseudocyst are also briefly discussed.
  • Haemothorax represents an unusual pulmonary complication of pseudocyst pancreas and should be considered in the differential diagnosis of pleural fluid collection in pancreatitis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 1979 Feb;34(1):106-12 [441988.001]
  • [Cites] Thorax. 1989 Oct;44(10):824-5 [2595625.001]
  • [Cites] Br Med J. 1973 Feb 10;1(5849):330-1 [4685624.001]
  • [Cites] Thorax. 1968 May;23(3):297-306 [4872925.001]
  • [Cites] Surg Clin North Am. 2001 Apr;81(2):307-20, ix-x [11392418.001]
  • [Cites] Ann Surg. 1968 Jan;167(1):112-5 [5299798.001]
  • [Cites] Clin Chest Med. 1998 Jun;19(2):407-17 [9646991.001]
  • [Cites] Surg Clin North Am. 1999 Aug;79(4):745-57, viii-ix [10470324.001]
  • [Cites] Am J Surg. 1972 Nov;124(5):600-6 [5079792.001]
  • (PMID = 20165665.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2822336
  • [Keywords] NOTNLM ; Haemothorax / Pseudocyst pancreas
  •  go-up   go-down


48. Fridell JA, Rogers J, Stratta RJ: The pancreas allograft donor: current status, controversies, and challenges for the future. Clin Transplant; 2010 Jul-Aug;24(4):433-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pancreas allograft donor: current status, controversies, and challenges for the future.
  • The pancreas allograft is a scarce resource that is currently underutilized.
  • The selection of appropriate deceased donors for pancreas procurement is of paramount importance for minimizing technical failure and optimizing long-term outcomes in pancreas transplantation.
  • Despite the increasing demand for pancreas transplantation, increases in overall organ donation rates and the evolution of criteria that constitute an "acceptable" pancreas donor, the number of deceased donor pancreas transplants being performed in the United States has actually declined in recent years.
  • Although there are many factors that must be considered during evaluation of the potential pancreas allograft donor to minimize morbidity and graft loss, it is evident that there are transplantable organs that are not used.
  • In this review, deceased donor pancreas identification, management, selection, allocation, assessment, preservation, and the problem of pancreas underutilization will be discussed.
  • [MeSH-major] Pancreas Transplantation / trends. Tissue Donors

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 John Wiley & Sons A/S.
  • (PMID = 20384731.001).
  • [ISSN] 1399-0012
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  •  go-up   go-down


49. Bradley SP, Kowalik TF, Rastellini C, da Costa MA, Bloomenthal AB, Cicalese L, Basadonna GP, Uknis ME: Successful incorporation of short-interfering RNA into islet cells by in situ perfusion. Transplant Proc; 2005 Jan-Feb;37(1):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the first successful introduction of siRNA directly into pancreatic islet cells both during in situ perfusion and from intravenous tail vein injection (in vivo).
  • METHODS: siRNA was targeted to the pancreatic islets of BALB/c mice by retrograde portal vein perfusion or tail vein injection.
  • After delivery pancreata were placed in cold storage at 4 degrees C in UW solution for 24 hours, followed by processing for immunofluorescent staining for insulin.
  • RESULTS: In situ delivery of siRNA was demonstrated by fluorescent imaging composites of (red) siRNA in and along (green) insulin stained islets from pancreas sections as compared with untreated control sections.
  • The siRNA was detected mainly in and along venous structures throughout the pancreatic tissue.
  • CONCLUSIONS: We have described the successful delivery of siRNA to pancreatic islets via a novel in situ pancreas perfusion technique and in vivo delivery via tail vein injection.

  • MedlinePlus Health Information. consumer health - Islet Cell Transplantation.
  • Hazardous Substances Data Bank. Allopurinol .
  • Hazardous Substances Data Bank. Adenosine .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15808605.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Insulin; 0 / Organ Preservation Solutions; 0 / RNA, Small Interfering; 0 / University of Wisconsin-lactobionate solution; 63CZ7GJN5I / Allopurinol; GAN16C9B8O / Glutathione; K72T3FS567 / Adenosine; N5O3QU595M / Raffinose
  •  go-up   go-down


50. Dalla Valle R, Capocasale E, Mazzoni MP, Busi N, Piazza P, Benozzi L, Sianesi M: Embolization of a ruptured pseudoaneurysm with massive hemorrhage following pancreas transplantation: a case report. Transplant Proc; 2005 Jun;37(5):2275-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embolization of a ruptured pseudoaneurysm with massive hemorrhage following pancreas transplantation: a case report.
  • We report a case of an arterioduodenal fistula related to a ruptured pseudoaneurysm after simultaneous pancreas-kidney transplantation (SPK) with massive gastrointestinal hemorrhage treated by embolization of the Y graft.
  • No rejection episodes were documented; the patient was discharged with normal pancreatic and renal function.
  • Few reports exist in the literature regarding the development of a pseudoaneurysm after pancreas transplantation.
  • [MeSH-major] Aneurysm, False / etiology. Aneurysm, Ruptured / etiology. Diabetes Mellitus, Type 1 / surgery. Embolization, Therapeutic. Gastrointestinal Hemorrhage / etiology. Pancreas Transplantation / adverse effects


51. Hayata T, Blitz IL, Iwata N, Cho KW: Identification of embryonic pancreatic genes using Xenopus DNA microarrays. Dev Dyn; 2009 Jun;238(6):1455-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of embryonic pancreatic genes using Xenopus DNA microarrays.
  • The pancreas is both an exocrine and endocrine endodermal organ involved in digestion and glucose homeostasis.
  • During embryogenesis, the anlagen of the pancreas arise from dorsal and ventral evaginations of the foregut that later fuse to form a single organ.
  • To better understand the molecular genetics of early pancreas development, we sought to isolate markers that are uniquely expressed in this tissue.
  • Microarray analysis was performed comparing dissected pancreatic buds, liver buds, and the stomach region of tadpole stage Xenopus embryos.
  • K-means clustering analysis predicted 120 of these genes to be specifically enriched in the pancreas.
  • Our analyses implicate the involvement of previously unsuspected signaling pathways during early pancreas development.
  • [MeSH-major] Oligonucleotide Array Sequence Analysis. Pancreas. Xenopus laevis

  • Xenbase. Xenbase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Development. 2004 Jul;131(13):3069-80 [15163629.001]
  • [Cites] Dev Cell. 2004 Jul;7(1):117-23 [15239959.001]
  • [Cites] Dev Genes Evol. 2004 Sep;214(9):432-41 [15322880.001]
  • [Cites] J Cell Biol. 1990 Mar;110(3):607-16 [1689730.001]
  • [Cites] Development. 1991 Oct;113(2):641-51 [1723680.001]
  • [Cites] EMBO J. 1992 Apr;11(4):1663-70 [1373383.001]
  • [Cites] Methods Cell Biol. 1991;36:685-95 [1811161.001]
  • [Cites] J Clin Invest. 1993 Jul;92(1):359-71 [8326004.001]
  • [Cites] Mol Cell Biol. 1994 Apr;14(4):2786-97 [8139576.001]
  • [Cites] Jpn J Cancer Res. 1995 Jul;86(7):655-61 [7559083.001]
  • [Cites] Development. 1996 Mar;122(3):983-95 [8631275.001]
  • [Cites] Development. 1996 May;122(5):1409-16 [8625829.001]
  • [Cites] Diabetologia. 1996 Apr;39(4):474-80 [8777998.001]
  • [Cites] Eur J Biochem. 1997 Oct 15;249(2):481-8 [9370357.001]
  • [Cites] Development. 1997 Nov;124(21):4243-52 [9334273.001]
  • [Cites] Mech Dev. 1998 Mar;72(1-2):27-40 [9533950.001]
  • [Cites] Genes Dev. 1998 Jun 1;12(11):1705-13 [9620856.001]
  • [Cites] Dev Dyn. 1998 Aug;212(4):509-21 [9707324.001]
  • [Cites] Cell. 1998 Aug 21;94(4):515-24 [9727494.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6267-72 [10339576.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):67-70 [10471501.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):71-5 [10471502.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):877-81 [10476967.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48329-41 [15322135.001]
  • [Cites] Cell. 2004 Nov 24;119(5):679-91 [15550249.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14037-42 [10570194.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Genet. 2000 Jan;24(1):36-44 [10615124.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):211-6 [10646608.001]
  • [Cites] Nature. 2000 Jan 13;403(6766):216-20 [10646609.001]
  • [Cites] Mol Cell Biol. 2000 Jun;20(12):4445-54 [10825208.001]
  • [Cites] Dev Dyn. 2000 Aug;218(4):615-27 [10906780.001]
  • [Cites] Dev Dyn. 2005 Feb;232(2):432-44 [15614765.001]
  • [Cites] Oncogene. 2005 Mar 3;24(10):1698-710 [15674337.001]
  • [Cites] Development. 2005 Mar;132(6):1337-48 [15750185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 5;102(14):4943-8 [15795378.001]
  • [Cites] Mol Cell Biol. 2005 Jun;25(12):5022-30 [15923619.001]
  • [Cites] Nature. 2005 Jun 16;435(7044):944-7 [15959514.001]
  • [Cites] Diabetologia. 2005 Aug;48(8):1510-22 [15991020.001]
  • [Cites] Dev Biol. 2005 Aug 15;284(2):399-411 [16026781.001]
  • [Cites] J Cell Sci. 2005 Sep 1;118(Pt 17):3839-47 [16091426.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31615-23 [16033762.001]
  • [Cites] Curr Biol. 2005 Sep 20;15(18):1677-83 [16169491.001]
  • [Cites] Diabetes. 2005 Oct;54(10):2844-51 [16186384.001]
  • [Cites] Development. 2005 Nov;132(21):4663-74 [16192304.001]
  • [Cites] Am J Pathol. 2006 Jan;168(1):9-19 [16400005.001]
  • [Cites] Semin Cell Dev Biol. 2006 Feb;17(1):133-45 [16337415.001]
  • [Cites] Semin Cell Dev Biol. 2006 Feb;17(1):99-109 [16356740.001]
  • [Cites] BMC Dev Biol. 2007;7:4 [17222338.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 10;104(15):6247-52 [17404238.001]
  • [Cites] Dev Dyn. 2007 Jun;236(6):1633-49 [17474120.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1817-31 [17639085.001]
  • [Cites] Dev Dyn. 2007 Aug;236(8):2321-30 [17615577.001]
  • [Cites] Mech Dev. 2007 Aug;124(7-8):518-31 [17643968.001]
  • [Cites] Blood. 2007 Oct 15;110(8):2889-98 [17644732.001]
  • [Cites] Development. 2007 Nov;134(22):4011-21 [17942484.001]
  • [Cites] EMBO J. 2007 Oct 31;26(21):4445-56 [17932483.001]
  • [Cites] Development. 2000 Oct;127(19):4179-93 [10976050.001]
  • [Cites] Development. 2000 Oct;127(20):4345-60 [11003835.001]
  • [Cites] Mech Dev. 2000 Nov;98(1-2):157-60 [11044621.001]
  • [Cites] Development. 2000 Nov;127(22):4905-13 [11044404.001]
  • [Cites] Development. 2000 Dec;127(24):5533-40 [11076772.001]
  • [Cites] Development. 2001 Jan;128(2):167-80 [11124113.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9640-8 [11136725.001]
  • [Cites] Mech Dev. 2001 May;103(1-2):153-7 [11335125.001]
  • [Cites] Development. 2001 Aug;128(15):2939-52 [11532917.001]
  • [Cites] Mol Cell Endocrinol. 2001 Dec 20;185(1-2):99-108 [11738799.001]
  • [Cites] Development. 2001 Dec;128(24):5109-17 [11748146.001]
  • [Cites] Genes Dev. 2002 Apr 15;16(8):893-907 [11959838.001]
  • [Cites] Mech Dev. 2002 May;113(2):153-7 [11960704.001]
  • [Cites] J Biol Chem. 2002 Aug 2;277(31):28271-9 [12145319.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):391-4 [12118252.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10488-93 [12149478.001]
  • [Cites] Curr Biol. 2002 Jul 23;12(14):1215-20 [12176331.001]
  • [Cites] Curr Opin Genet Dev. 2002 Oct;12(5):540-7 [12200159.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):128-34 [12185368.001]
  • [Cites] Dev Cell. 2003 Mar;4(3):383-93 [12636919.001]
  • [Cites] Dev Dyn. 2003 Apr;226(4):663-74 [12666204.001]
  • [Cites] Dev Growth Differ. 2003 Apr;45(2):143-52 [12752502.001]
  • [Cites] Development. 2003 Aug;130(16):3865-76 [12835401.001]
  • [Cites] Genomics. 2003 Aug;82(2):130-42 [12837264.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):26166-73 [12682071.001]
  • [Cites] J Biol Chem. 2003 Jul 11;278(28):25671-7 [12730235.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35725-31 [12853459.001]
  • [Cites] Mol Cell Biol. 2003 Oct;23(19):6713-24 [12972592.001]
  • [Cites] Annu Rev Cell Dev Biol. 2003;19:71-89 [14570564.001]
  • [Cites] Gene Expr Patterns. 2004 Jan;4(1):71-6 [14678831.001]
  • [Cites] Development. 2004 Jan;131(1):165-79 [14660441.001]
  • [Cites] Exp Cell Res. 2004 Mar 10;294(1):18-29 [14980497.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] BMJ. 2004 Mar 27;328(7442):750-4 [15044291.001]
  • [Cites] Mol Cell Endocrinol. 2004 Feb 12;214(1-2):149-53 [15062553.001]
  • [Cites] Genes Immun. 2004 May;5(3):232-5 [14961073.001]
  • [Cites] Development. 2004 May;131(10):2431-41 [15128672.001]
  • [Cites] J Biol Chem. 2004 May 14;279(20):21206-16 [15014077.001]
  • [Cites] Dev Biol. 2004 Jul 1;271(1):144-60 [15196957.001]
  • (PMID = 19191222.001).
  • [ISSN] 1058-8388
  • [Journal-full-title] Developmental dynamics : an official publication of the American Association of Anatomists
  • [ISO-abbreviation] Dev. Dyn.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / R01 HD029507; United States / NICHD NIH HHS / HD / R01 HD056219
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Frizzled Receptors; 0 / Hedgehog Proteins; 0 / Immunoglobulin J Recombination Signal Sequence-Binding Protein; 0 / Receptors, G-Protein-Coupled; 0 / Wnt Proteins; 0 / Xenopus Proteins; 0 / fzd10a protein, Xenopus; 62031-54-3 / Fibroblast Growth Factors
  • [Other-IDs] NLM/ NIHMS283451; NLM/ PMC4203858
  •  go-up   go-down


52. Kato M, Kubota K, Kita J, Shimoda M, Rokkaku K, Inaba N, Fukasawa I, Honma K: Huge mucinous cystadenoma of the pancreas developing during pregnancy: a case report. Pancreas; 2005 Mar;30(2):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge mucinous cystadenoma of the pancreas developing during pregnancy: a case report.
  • A tentative diagnosis of ovarian or pancreatic mucinous cystadenoma was made.
  • The cyst was found to originate from the pancreas, and distal pancreatectomy with splenectomy was performed.
  • Histological diagnosis was a benign mucinous cystadenoma.
  • Up to the present, there have been three reported cases of pancreatic mucinous cystadenoma, including our case, and two cases of pancreatic mucinous cystadenocarcinoma, in association with pregnancy.
  • Our case is the third reported of successful resection of the tumor during pregnancy resulting in a healthy infant.
  • [MeSH-major] Cystadenoma, Mucinous / pathology. Pancreatic Neoplasms / pathology. Pregnancy Complications, Neoplastic


53. Pogue BW, Samkoe KS, Hextrum S, O'Hara JA, Jermyn M, Srinivasan S, Hasan T: Imaging targeted-agent binding in vivo with two probes. J Biomed Opt; 2010 May-Jun;15(3):030513
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Images of a binding rate constant are created that reveal lower than expected uptake of epidermal growth factor in an orthotopic xenograft pancreas tumor (2.3 x 10(-5) s(-1)), as compared to the normal pancreas (3.4 x 10(-5) s(-1)).
  • This approach allows noninvasive assessment of tumor receptor targeting in vivo to determine the expected contrast, spatial localization, and efficacy in therapeutic agent delivery.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 2003 Nov;186(5):431-6 [14599602.001]
  • [Cites] Crit Rev Ther Drug Carrier Syst. 1992;9(2):135-87 [1386002.001]
  • [Cites] Nat Biotechnol. 2005 Sep;23(9):1147-57 [16151408.001]
  • [Cites] J Clin Oncol. 2009 Nov 20;27(33):5660-9 [19858397.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15549-54 [17875985.001]
  • [Cites] Breast Cancer Res Treat. 2008 May;109(2):209-29 [17636396.001]
  • [Cites] Cancer Biomark. 2005;1(2-3):157-75 [17192037.001]
  • (PMID = 20614996.001).
  • [ISSN] 1560-2281
  • [Journal-full-title] Journal of biomedical optics
  • [ISO-abbreviation] J Biomed Opt
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA084203; United States / NCI NIH HHS / CA / R01 CA109558; United States / NCI NIH HHS / CA / P01CA84203; United States / NCI NIH HHS / CA / R01CA109558
  • [Publication-type] Letter; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorescent Dyes; 62229-50-9 / Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2909298
  •  go-up   go-down


54. Novellas S, Chevallier P, Saint Paul MC, Gugenheim J, Bruneton JN: MRI features of a pancreatic schwannoma. Clin Imaging; 2005 Nov-Dec;29(6):434-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI features of a pancreatic schwannoma.
  • A case of a pancreatic schwannoma is presented.
  • The patient, a previously healthy woman, is hospitalized with the diagnosis of purulent pleuritis.
  • Ultrasonography (US) of the abdomen shows a 3-cm mass in the head of the pancreas.
  • A duodenopancreatotomy is performed, and the pathologic specimen demonstrates a schwannoma of the pancreas with Antoni A pattern.
  • [MeSH-major] Neurilemmoma / diagnosis. Pancreatic Neoplasms / diagnosis
  • [MeSH-minor] Contrast Media. Diagnosis, Differential. Female. Gadolinium DTPA. Humans. Magnetic Resonance Imaging. Middle Aged

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274899.001).
  • [ISSN] 0899-7071
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


55. Ibis C, Albayrak D, Altan A: Primary hydatid disease of pancreas mimicking cystic neoplasm. South Med J; 2009 May;102(5):529-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hydatid disease of pancreas mimicking cystic neoplasm.
  • Primary hydatid disease of the pancreas is very rare.
  • We report a 33-year-old female who was admitted to the hospital with abdominal discomfort due to the pancreatic mass.
  • A diagnosis of a pancreatic cystic mass was established through abdominal ultrasonography and computed tomography scan.
  • Hydatid disease as well as a cystic neoplasm of the pancreas were both thought in the differential diagnosis.
  • The histopathologic evaluation of the specimen revealed a hydatid cyst affecting the tail of the pancreas.
  • Hydatid disease should be considered in the differential diagnosis of all cystic masses of the pancreas, especially in endemic regions.
  • [MeSH-major] Echinococcosis / diagnosis. Pancreatic Diseases / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19373169.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Szmidt J, Gałazka Z, Frunze S, Grochowiecki T, Nazarewski S, Durlik M, Jakimowicz T, Wojtaszek M, Grygiel K, Paczek L: Secondary kidney transplantation in a patient 16 years after simultaneous pancreas and kidney transplantation--a case report. Ann Transplant; 2006;11(1):40-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary kidney transplantation in a patient 16 years after simultaneous pancreas and kidney transplantation--a case report.
  • Simultaneous pancreas and kidney transplantation (spktx) is currently the most effective method of treatment of type 1 diabetes complicated by renal insufficiency.
  • [MeSH-major] Kidney Transplantation / physiology. Pancreas Transplantation / physiology. Reoperation


57. Mirarchi M, De Raffele E, Lega S, Calculli L, Vaccari S, Cola B: [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient]. Chir Ital; 2009 May-Jun;61(3):357-67
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous adenocarcinoma of the sigmoid colon and multifocal intraductal papillary mucinous neoplasm of the pancreas in an elderly patient].
  • [Transliterated title] Adenocarcinoma del colon e neoplasia papillare intraduttale mucinosa multifocale sincrona del pancreas in un paziente anziano: caso clinico e revisione della letteratura.
  • Intraductal papillary mucinous neoplasms are a well-recognized pathologic entity of the pancreas that is being reported with increasing frequency.
  • A 78-year-old man presented with rectal bleeding which led to the diagnosis of a stenosing adenocarcinoma of the sigmoid colon.
  • No metastatic lesions were present but a 30 mm intraductal papillary mucinous neoplasm with mural nodules was detected in the uncinate process of the pancreas.
  • Histology showed a combined-type intraductal papillary mucinous neoplasm with foci of non-invasive carcinoma.
  • The co-existence of a potentially malignant pancreatic tumour with an extra-pancreatic overt malignancy in elderly patients poses difficulties in the attempt to cure the patient with minimal morbidity.
  • In the present case we considered a staged surgical procedure with the aim of reducing the perioperative risk, since the excision of the pancreatic neoplasm required a pancreaticoduodenectomy in an elderly patient.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Neoplasms, Multiple Primary / pathology. Pancreatic Neoplasms / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Aged. Colectomy / methods. Humans. Male. Neoplasm Staging. Pancreaticoduodenectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19694240.001).
  • [ISSN] 0009-4773
  • [Journal-full-title] Chirurgia italiana
  • [ISO-abbreviation] Chir Ital
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


58. Kanno A, Satoh K, Hirota M, Hamada S, Umino J, Itoh H, Masamune A, Asakura T, Shimosegawa T: Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas. J Gastroenterol; 2010 Sep;45(9):952-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of invasive carcinoma in branch type intraductal papillary mucinous neoplasms of the pancreas.
  • BACKGROUND: Patients with branch duct type intraductal papillary mucinous neoplasm (BD-IPMN) without invasion usually show favorable prognosis.
  • In addition, recent studies have revealed that BD-IPMN is frequently complicated by common type pancreatic ductal carcinoma.
  • METHODS: Invasive pancreatic carcinoma associating with BD-IPMN was classified as invasive IPMN group (invasive carcinoma derived directly from IPMN lesions) and concomitant group (common type of invasive carcinoma concomitant with BD-IPMN).
  • Diameter of dilated branch (P < 0.001) or main pancreatic duct (MPD) (P = 0.001), size of mural nodule (P < 0.001), serum CEA level (P < 0.001) and serum CA19-9 level (P < 0.001) were factors associated significantly with invasive IPMN by univariate analysis.
  • CONCLUSIONS: Our results suggested that careful imaging study of the entire pancreas in addition to tumor lesions and measurement of serum CEA and CA19-9 would be required to find out the development of the two types of invasive carcinoma in BD-IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. Retrospective Studies. Risk Factors

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2008 Sep;248(3):876-86 [18632526.001]
  • [Cites] Gastroenterology. 2002 Nov;123(5):1500-7 [12404225.001]
  • [Cites] Gut. 2002 Nov;51(5):717-22 [12377813.001]
  • [Cites] Hepatogastroenterology. 2004 Sep-Oct;51(59):1480-3 [15362782.001]
  • [Cites] Virchows Arch. 1994;425(4):357-67 [7820300.001]
  • [Cites] Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9 [15166958.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1244-9 [14515294.001]
  • [Cites] Pancreatology. 2006;6(1-2):17-32 [16327281.001]
  • [Cites] Am J Surg Pathol. 1995 May;19(5):576-89 [7726368.001]
  • [Cites] Am J Gastroenterol. 2002 Oct;97(10):2553-8 [12385438.001]
  • [Cites] Arch Surg. 1999 Oct;134(10 ):1131-6 [10522860.001]
  • [Cites] Ann Surg. 1997 Oct;226(4):491-8; discussion 498-500 [9351717.001]
  • [Cites] Am J Surg. 1996 Apr;171(4):427-31 [8604836.001]
  • [Cites] Pancreas. 2004 Apr;28(3):241-6 [15084964.001]
  • [Cites] J Gastrointest Surg. 2003 Jan;7(1):12-8; discussion 18-9 [12559180.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Oct;4(10):1265-70 [16979953.001]
  • [Cites] Hepatogastroenterology. 1998 Nov-Dec;45(24):1973-80 [9951850.001]
  • [Cites] Surgery. 2002 Jul;132(1):80-5 [12110799.001]
  • [Cites] J Clin Gastroenterol. 2003 Mar;36(3):261-5 [12590239.001]
  • [Cites] Gastrointest Endosc. 1998 Jan;47(1):42-9 [9468422.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1372-7 [11023098.001]
  • [Cites] Am J Gastroenterol. 2007 Aug;102(8):1759-64 [17686073.001]
  • [Cites] Gut. 2008 Mar;57(3):339-43 [17660227.001]
  • [Cites] Pancreatology. 2002;2(5):484-90 [12378117.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):313-21; discussion 321-2 [11524584.001]
  • [Cites] Cancer. 1991 Jul 1;68(1):159-68 [2049738.001]
  • [Cites] Ann Surg. 2004 May;239(5):678-85; discussion 685-7 [15082972.001]
  • [Cites] Korean J Radiol. 2003 Jul-Sep;4(3):157-62 [14530644.001]
  • [Cites] Clin Gastroenterol Hepatol. 2008 Jul;6(7):815-9; quiz 719 [18602036.001]
  • [Cites] Gut. 2008 Nov;57(11):1561-5 [18477671.001]
  • [Cites] Hepatogastroenterology. 1996 May-Jun;43(9):692-709 [8799417.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):651-6 [1309676.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):644-51; discussion 651-4 [17893501.001]
  • [Cites] Hepatogastroenterology. 2000 Jul-Aug;47(34):1129-34 [11020896.001]
  • (PMID = 20383536.001).
  • [ISSN] 1435-5922
  • [Journal-full-title] Journal of gastroenterology
  • [ISO-abbreviation] J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


59. Flamez D, Roland I, Berton A, Kutlu B, Dufrane D, Beckers MC, De Waele E, Rooman I, Bouwens L, Clark A, Lonneux M, Jamar JF, Goldman S, Maréchal D, Goodman N, Gianello P, Van Huffel C, Salmon I, Eizirik DL: A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker. Diabetologia; 2010 Jul;53(7):1372-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A genomic-based approach identifies FXYD domain containing ion transport regulator 2 (FXYD2)gammaa as a pancreatic beta cell-specific biomarker.
  • AIMS/HYPOTHESIS: Non-invasive imaging of the pancreatic beta cell mass (BCM) requires the identification of novel and specific beta cell biomarkers.
  • For four of the proteins we selected or produced antibodies targeting specifically the human proteins and their splice variants; all four candidates were confirmed as islet-specific in human pancreas.
  • Two splice variants of FXYD domain containing ion transport regulator 2 (FXYD2), a regulating subunit of the Na(+)-K(+)-ATPase, were identified as preferentially present in human pancreatic islets.
  • The presence of FXYD2gammaa was restricted to pancreatic islets and selectively detected in pancreatic beta cells.
  • Analysis of human fetal pancreas samples showed the presence of FXYD2gammaa at an early stage (15 weeks).
  • Histological examination of pancreatic sections from individuals with type 1 diabetes or sections from pancreases of streptozotocin-treated Macacus cynomolgus monkeys indicated a close correlation between loss of FXYD2gammaa and loss of insulin-positive cells.


60. Ikemoto T, Noguchi H, Shimoda M, Naziruddin B, Jackson A, Tamura Y, Fujita Y, Onaca N, Levy MF, Matsumoto S: Islet cell transplantation for the treatment of type 1 diabetes in the USA. J Hepatobiliary Pancreat Surg; 2009;16(2):118-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ICTx requires complex procedures, including pancreas procurement and preservation; pancreas digestion; islet purification; and transplantation.
  • A new preservation strategy for pancreata and pancreatic ducts using ET-Kyoto solution as well as a new islet purification method using iodixanol has substantially improved islet yields.


61. Dotta F, Galleri L, Sebastiani G, Vendrame F: Virus infections: lessons from pancreas histology. Curr Diab Rep; 2010 Oct;10(5):357-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virus infections: lessons from pancreas histology.
  • Type 1 diabetes mellitus is a chronic autoimmune disease resulting from the progressive immune-mediated destruction of pancreatic beta cells in genetically susceptible individuals, with the likely contribution of environmental factors, among which viruses have been extensively studied.
  • We review the recent literature on the viral contribution to beta-cell destruction and dysfunction in type 1 diabetes, with particular reference to the pathology of the pancreatic islet in humans and in animal models of the disease.
  • [MeSH-major] Pancreas / pathology. Pancreas / virology. Virus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Viral Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Virol. 1986;87(1-2):143-50 [3002301.001]
  • [Cites] Acta Virol. 1994 Oct;38(5):251-5 [7725998.001]
  • [Cites] Diabetes. 2010 May;59(5):1182-91 [20071599.001]
  • [Cites] Pancreas. 2010 Jan;39(1):47-56 [19770783.001]
  • [Cites] BMJ. 2004 Mar 27;328(7442):750-4 [15044291.001]
  • [Cites] J Interferon Res. 1991 Oct;11(5):255-60 [1723088.001]
  • [Cites] Ann N Y Acad Sci. 2009 Sep;1173:442-8 [19758184.001]
  • [Cites] Diabetes. 2000 Aug;49(8):1314-8 [10923631.001]
  • [Cites] Exp Diabetes Res. 2009;2009:631026 [19888425.001]
  • [Cites] Diabetes. 2005 May;54(5):1588-91 [15855350.001]
  • [Cites] J Clin Invest. 2009 Jun;119(6):1515-23 [19478458.001]
  • [Cites] Virology. 2004 Nov 24;329(2):381-94 [15518817.001]
  • [Cites] J Clin Virol. 2010 Mar;47(3):224-8 [20097601.001]
  • [Cites] Diabetes. 2002 Jun;51(6):1964-71 [12031987.001]
  • [Cites] Ann N Y Acad Sci. 2003 Nov;1005:13-22 [14679036.001]
  • [Cites] Nature. 2009 May 28;459(7246):518-9 [19478773.001]
  • [Cites] Diabetes. 1996 Jun;45(6):818-21 [8635659.001]
  • [Cites] Clin Exp Immunol. 2010 Mar;159(3):338-43 [20059481.001]
  • [Cites] Diabetes. 2000 May;49(5):708-11 [10905477.001]
  • [Cites] Rev Med Virol. 2010 Mar;20(2):106-16 [20049905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):5115-20 [17360338.001]
  • [Cites] Diabetologia. 2009 Jun;52(6):1143-51 [19266182.001]
  • [Cites] Diabetes. 2007 Apr;56(4):1059-68 [17395746.001]
  • [Cites] Nat Rev Endocrinol. 2009 Apr;5(4):219-26 [19352320.001]
  • [Cites] Hum Mol Genet. 2010 Jan 1;19(1):135-46 [19825843.001]
  • [Cites] Diabetologia. 2004 Feb;47(2):225-39 [14727023.001]
  • [Cites] Semin Immunopathol. 2011 Jan;33(1):57-66 [20383637.001]
  • [Cites] Cell. 1991 Apr 19;65(2):319-31 [1901765.001]
  • [Cites] Clin Exp Immunol. 2009 Feb;155(2):173-81 [19128359.001]
  • [Cites] J Med Virol. 2009 Feb;81(2):296-304 [19107967.001]
  • [Cites] Nat Med. 1998 Jul;4(7):781-5 [9662368.001]
  • [Cites] Trends Mol Med. 2008 Jun;14 (6):268-75 [18482868.001]
  • [Cites] Science. 2009 Apr 17;324(5925):387-9 [19264985.001]
  • [Cites] Diabetologia. 2009 Jun;52(6):995-6 [19322560.001]
  • [Cites] J Virol. 2002 Dec;76(23):12097-111 [12414951.001]
  • [Cites] Diabetes. 2009 Feb;58(2):344-51 [19008341.001]
  • [Cites] Diabetes. 2009 Oct;58(10):2285-91 [19641142.001]
  • [Cites] Diabetologia. 2010 Apr;53(4):690-8 [20062967.001]
  • [Cites] J Clin Invest. 2002 Jan;109(1):79-87 [11781353.001]
  • [Cites] Diabetes Metab. 2008 Dec;34(6 Pt 1):537-48 [18951821.001]
  • [Cites] J Autoimmun. 2001 May;16(3):211-7 [11334485.001]
  • (PMID = 20665131.001).
  • [ISSN] 1539-0829
  • [Journal-full-title] Current diabetes reports
  • [ISO-abbreviation] Curr. Diab. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  •  go-up   go-down


62. Meier R, Ockenga J, Pertkiewicz M, Pap A, Milinic N, Macfie J, DGEM (German Society for Nutritional Medicine), Löser C, Keim V, ESPEN (European Society for Parenteral and Enteral Nutrition): ESPEN Guidelines on Enteral Nutrition: Pancreas. Clin Nutr; 2006 Apr;25(2):275-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ESPEN Guidelines on Enteral Nutrition: Pancreas.
  • The two major forms of inflammatory pancreatic diseases, acute and chronic pancreatitis, require different approaches in nutritional management, which are presented in the present guideline.
  • In chronic pancreatitis more than 80% of patients can be treated adequately with normal food supplemented by pancreatic enzymes.

  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16678943.001).
  • [ISSN] 0261-5614
  • [Journal-full-title] Clinical nutrition (Edinburgh, Scotland)
  • [ISO-abbreviation] Clin Nutr
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] England
  • [Number-of-references] 78
  •  go-up   go-down


63. Kraemer A, Lewin M, Balladur P, Mourra N, Tiret E, Paye F: [Autoimmune pancreatitis mimicking an intra-ductal papillary mucinous neoplasm of the pancreas: an original case]. Gastroenterol Clin Biol; 2008 Jun-Jul;32(6-7):635-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Autoimmune pancreatitis mimicking an intra-ductal papillary mucinous neoplasm of the pancreas: an original case].
  • [Transliterated title] Pancréatite auto-immune mimant une tumeur intracanalaire papillaire et mucineuse : une observation originale et trompeuse.
  • It can be associated with diabetes mellitus and other systemic autoimmune diseases, or with bile ducts lesions, which are also responsive to steroid therapy as pancreatic lesions.
  • We report the case of a 34-year-old man with a history of a first acute pancreatitis, attributed to an intraductal papillary-mucinous neoplasm of the pancreas (IPMN) with segmental involvement of the main pancreatic duct.
  • To our knowledge, this is the first reported case of AIP mimicking IPMN of the main pancreatic duct.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Autoimmune Diseases / diagnosis. Carcinoma, Papillary / diagnosis. Pancreatic Neoplasms / diagnosis. Pancreatitis / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male


64. Tian JY, Li G, Gu YY, Zhang HL, Zhou WZ, Wang X, Zhu HD, Luo TH, Luo M: Role and mechanism of rosiglitazone on the impairment of insulin secretion induced by free fatty acids on isolated rat islets. Chin Med J (Engl); 2006 Apr 5;119(7):574-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Prolonged exposure of pancreatic beta-cells to fatty acids increases basal insulin secretion but inhibits glucose-stimulated insulin secretion.
  • METHODS: Pancreatic islets were isolated from the pancreata of male Sprague-Dawley rats by the collagenase digestion and by the dextran gradient centrifugation method.
  • CONCLUSION: The protective effects of rosiglitazone on insulin secretion of isolated pancreatic islets under chronic exposure to palmitate might be mediated through the downregulation of UCP-2 expression.

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ROSIGLITAZONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16620699.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fatty Acids, Nonesterified; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Ion Channels; 0 / Membrane Transport Proteins; 0 / Mitochondrial Proteins; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Thiazolidinediones; 0 / mitochondrial uncoupling protein 2; 05V02F2KDG / rosiglitazone
  •  go-up   go-down


65. Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM: Antibody-mediated rejection of a pancreas allograft. Am J Transplant; 2006 Feb;6(2):423-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody-mediated rejection of a pancreas allograft.
  • The role of antibody-mediated rejection (AMR) in pancreas transplantation is poorly understood.
  • Here, we report on a patient who developed AMR of his pancreas allograft after receiving a simultaneous pancreas-kidney transplant.
  • A pancreatic biopsy at this time showed no cellular infiltrate but strong immunofluorescent staining for C4d in the interacinar capillaries.
  • He received intravenous immunoglobulin (IVIg), rituximab and plasmapheresis, and his pancreatic function normalized.
  • We conclude that clinically significant AMR can develop in a pancreas allograft and recommend that pancreatic biopsies be assessed for C4d deposition if the patient has risk factors for AMR and/or the pathologic evidence for cell-mediated rejection is underwhelming.

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16426331.001).
  • [ISSN] 1600-6135
  • [Journal-full-title] American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons
  • [ISO-abbreviation] Am. J. Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Isoantibodies
  •  go-up   go-down


66. Colović R, Grubor N, Misev M, Jovanović M, Radak V: [Fibromyxoid sarcoma of the pancreas]. Srp Arh Celok Lek; 2008 Mar-Apr;136(3-4):158-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Fibromyxoid sarcoma of the pancreas].
  • INTRODUCTION: Fibromyxoid sarcoma is a rare mesenchymal neoplasm, usually appearing in the soft tissue of the extremities, less frequently in the groin, trunk, neck, and upper extremities.
  • Within the abdomen, the tumour is usually localised within the retroperitoneum.
  • CASE OUTLINE: We present a 56-year-old woman in whom, during the routinely performed investigation for atacks of choking with lots of bronchial secretion, and arterial hypertension, an ultrasonographer found a tumour within the head of the pancreas 6 x 6 cm in diameter.
  • At operation, a dark pink, lobulated soft tumour, surrounded by a tiny capsule, clearly different from the completely normal pancreatic tissue of the posterior side of the head of the pancreas, was easily and ideally excised.
  • The histology of the 80 g weighing tumour showed a circumscribed fibromyxoid sarcoma of low malignancy.
  • CONCLUSION: Primary sarcomas of the pancreas are very rare, but should be considered in differential diagnosis of pancreatic neoplasms.
  • To the best of our knowledge, there has been no previously described fibromyxoid sarcoma of the pancreas.
  • [MeSH-major] Fibrosarcoma / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18720751.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


67. Kongkam P, Wagner DL, Sherman S, Fogel EL, Whittaker SC, Watkins JL, McHenry L, Lehman GA: Intrathecal narcotic infusion pumps for intractable pain of chronic pancreatitis: a pilot series. Am J Gastroenterol; 2009 May;104(5):1249-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • ITNP offers the advantages of reversibility, lower total narcotic dose, and the pancreas remaining intact.
  • Each patient had multiple other failed treatment modalities, including partial pancreatic resection (n = 6).
  • Etiologies of CP included idiopathy (n = 3), cystic fibrosis (n = 2), alcohol (n = 2), and pancreas divisum (n = 6).

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19367269.001).
  • [ISSN] 1572-0241
  • [Journal-full-title] The American journal of gastroenterology
  • [ISO-abbreviation] Am. J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics
  •  go-up   go-down


68. Li Z, Korzh V, Gong Z: DTA-mediated targeted ablation revealed differential interdependence of endocrine cell lineages in early development of zebrafish pancreas. Differentiation; 2009 Nov;78(4):241-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DTA-mediated targeted ablation revealed differential interdependence of endocrine cell lineages in early development of zebrafish pancreas.
  • In order to study the zebrafish endocrine pancreas cell lineage, transgenic expression of diphtheria toxin gene A chain (DTA) under two cell type-specific promoters derived from the insulin (ins) and somatostatin2 (sst2) genes was used to ablate the two types of endocrine cells: insulin-producing beta-cells and somatostatin-producing delta-cells, respectively.
  • [MeSH-major] Glucagon-Secreting Cells / metabolism. Islets of Langerhans / cytology. Pancreas / cytology. Somatostatin-Secreting Cells / metabolism. Zebrafish / genetics

  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19553000.001).
  • [ISSN] 1432-0436
  • [Journal-full-title] Differentiation; research in biological diversity
  • [ISO-abbreviation] Differentiation
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphtheria Toxin; 0 / Insulin; 0 / Peptide Fragments; 0 / diphtheria toxin fragment A; 147336-22-9 / Green Fluorescent Proteins; 51110-01-1 / Somatostatin
  •  go-up   go-down


69. Junior RF, Kubrusly MS, Bellodi-Privato M, Molan NA, Machado MC, D'Albuquerque LA: Beneficial effects of N-acetyl cysteine on pancreas and kidney following experimental pancreatic ischemia-reperfusion in rats. Clinics (Sao Paulo); 2010 Mar;65(3):311-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beneficial effects of N-acetyl cysteine on pancreas and kidney following experimental pancreatic ischemia-reperfusion in rats.
  • OBJECTIVE: To evaluate the protective effects of N-acetyl cysteine on the pancreas and kidney after pancreatic ischemia reperfusion injury in a rat model.
  • METHODS AND MATERIALS: Pancreatic ischemia reperfusion was performed in Wistar rats for 1 hour.
  • A total of 24 animals were divided into four groups: Group 1: sham; Group 2: pancreatic ischemia reperfusion without treatment; Group 3: pancreatic ischemia reperfusion plus N-acetyl cysteine intravenously; and Group 4: pancreatic ischemia reperfusion plus N-acetyl cysteine per os.
  • RESULTS: There were significant differences in amylase levels between Group 1 (6.11+/-0.55) and Group 2 (10.30+/-0.50) [p=0.0002] as well as between Group 2 (10.30+/-0.50) and Group 4 (7.82+/-0.38) [p=0.003]; creatinine levels between Group 1 (0.52 +/- 0.07) and Group 2 (0.77+/-0.18) [p=0.035] as well as between Group 2 (0.77+/-0.18) and Group 3 (0.48+/-0.13) [p=0.012]; and pancreatic tissue thiobarbituric acid reactive substance levels between Group 1 (1.27+/-0.96) and Group 2 (2.60+/-3.01) [p=0.026] as well as between Group 2 (2.60+/-3.01) and Group 4 (0.52+/-0.56) [p=0.002].
  • A decrease in pancreatic tissue GST-alpha3 gene expression was observed in Group 2 in comparison to Group 1 (p =0.006), and an increase was observed in Groups 3 and 4 when compared to Group 2 (p= 0.025 and p=0.010, respectively).
  • CONCLUSION: This study provides evidence that N-acetyl cysteine has a beneficial effect on pancreatic ischemia reperfusion injury and renal function in a rat model.
  • [MeSH-major] Acetylcysteine / pharmacology. Kidney / drug effects. Pancreas / drug effects. Reperfusion Injury / drug therapy

  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] J Surg Res. 2010 May 1;160(1):163-8 [19628223.001]
  • [Cites] J Physiol Pharmacol. 2001 Jun;52(2):221-35 [11453102.001]
  • [Cites] Shock. 2002 Apr;17(4):286-92 [11954828.001]
  • [Cites] Free Radic Res. 2002 Mar;36(3):329-40 [12071352.001]
  • [Cites] Transplant Proc. 2002 Sep;34(6):2369-71 [12270441.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):e45 [11328886.001]
  • [Cites] Life Sci. 2003 May 2;72(24):2707-18 [12679188.001]
  • [Cites] Langenbecks Arch Chir Suppl Kongressbd. 1998;115(Suppl I):147-51 [14518230.001]
  • [Cites] Diabetes Care. 2004 Jan;27 Suppl 1:S105 [14693941.001]
  • [Cites] Pharmacol Res. 2004 Mar;49(3):227-38 [14726217.001]
  • [Cites] J Hepatol. 2004 Apr;40(4):632-7 [15030979.001]
  • [Cites] Transplantation. 2004 Sep 15;78(5):654-9 [15371664.001]
  • [Cites] J Dent Res. 1969 May-Jun;48(3):483 [5254492.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1429-32 [7504566.001]
  • [Cites] Hepatogastroenterology. 1993 Oct;40(5):452-6 [7505764.001]
  • [Cites] Transplant Proc. 1994 Feb;26(1):316-20 [8108998.001]
  • [Cites] Transplantation. 1995 Jan 15;59(1):6-9 [7839430.001]
  • [Cites] Am J Physiol. 1995 Jun;268(6 Pt 1):G988-96 [7611420.001]
  • [Cites] Acta Physiol Scand. 1995 Aug;154(4):461-8 [7484172.001]
  • [Cites] Free Radic Biol Med. 1995 Nov;19(5):627-38 [8529922.001]
  • [Cites] Gut. 1996 Sep;39(3):407-15 [8949646.001]
  • [Cites] Liver Transpl Surg. 1998 Mar;4(2):152-7 [9516568.001]
  • [Cites] Clin Chim Acta. 1998 Jul 28;275(2):127-35 [9721071.001]
  • [Cites] Transplantation. 2004 Dec 27;78(12):1802-8 [15614154.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2005;45:51-88 [15822171.001]
  • [Cites] Kidney Int. 2005 Nov;68(5):2208-17 [16221220.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1428-34 [16732181.001]
  • [Cites] Free Radic Biol Med. 2007 Mar 15;42(6):882-92 [17320770.001]
  • [Cites] J Hypertens. 2001 Jul;19(7):1233-44 [11446713.001]
  • (PMID = 20360923.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2845773
  • [Keywords] NOTNLM ; Ischemia / N-Acetyl Cysteine / Pancreas / Reperfusion / Transplantation
  •  go-up   go-down


70. Rautou PE, Lévy P, Vullierme MP, O'Toole D, Couvelard A, Cazals-Hatem D, Palazzo L, Aubert A, Sauvanet A, Hammel P, Hentic O, Rebours V, Pelletier AL, Maire F, Ruszniewski P: Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study. Clin Gastroenterol Hepatol; 2008 Jul;6(7):807-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Morphologic changes in branch duct intraductal papillary mucinous neoplasms of the pancreas: a midterm follow-up study.
  • BACKGROUND & AIMS: Because there is a low risk of malignancy for intraductal papillary and mucinous neoplasms of the pancreas (IPMNs) confined to branch ducts (BD), patient follow-up evaluation without surgery is possible.
  • METHODS: All consecutive patients seen from 1999 to 2005 with highly suspected IPMNs confined to BD without criteria suggesting a malignant development (mural nodule, cyst wall thickness >2 mm, BD diameter >30 mm, or main pancreatic duct involvement) were followed up prospectively using computerized tomography, magnetic resonance cholangiopancreatography, and endoscopic ultrasonography.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2008 Jul;6(7):724-5 [18602034.001]
  • (PMID = 18304885.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Malek SK, Potdar S, Martin JA, Tublin M, Shapiro R, Fung JJ: Percutaneous ultrasound-guided pancreas allograft biopsy: a single-center experience. Transplant Proc; 2005 Dec;37(10):4436-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous ultrasound-guided pancreas allograft biopsy: a single-center experience.
  • Percutaneous ultrasound-guided pancreas allograft biopsy is the preferred technique for evaluating pancreas allograft rejection.
  • Thirty-three patients received simultaneous pancreas and kidney transplants, 14 received isolated pancreas transplants, and 7 received a pancreas transplant after kidney transplantation.
  • Biopsies were performed by pancreas transplantation surgeons with the assistance of radiologists under ultrasound guidance using an Acuson XP 128/10 ultrasound machine.
  • Eighteen (15%) biopsy samples had no pancreatic tissue and showed surrounding fat and small bowel.
  • One (1.8%) patient had a pancreatic fistula, which healed with nonoperative management.
  • Percutaneous ultrasound-guided pancreas allograft biopsy is a safe procedure with a low complication rate and a high tissue yield for histopathologic examination.
  • [MeSH-major] Pancreas Transplantation / pathology. Ultrasonography
  • [MeSH-minor] Biopsy. Humans. Kidney Transplantation / pathology. Pancreas / pathology. Pancreas / ultrasonography. Retrospective Studies. Transplantation, Homologous / pathology

  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • MedlinePlus Health Information. consumer health - Ultrasound.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16387139.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Mainra R, Elder GJ: Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation. Clin J Am Soc Nephrol; 2010 Jan;5(1):117-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation.
  • BACKGROUND AND OBJECTIVES: Most patients who undergo kidney or kidney-pancreas transplantation have renal osteodystrophy, and immediately after transplantation bone mineral density (BMD) commonly falls.
  • DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A total of 153 kidney (61%) and kidney-pancreas (39%) transplant recipients were allocated to bisphosphonate (62%) or calcitriol (38%) therapy using an algorithm that incorporated BMD, prevalent vertebral fracture, biomarkers of bone turnover, and risk factor assessment.
  • [MeSH-major] Bone Density. Bone Density Conservation Agents / therapeutic use. Calcitriol / therapeutic use. Diphosphonates / therapeutic use. Kidney Transplantation / adverse effects. Pancreas Transplantation / adverse effects

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Clin Invest. 2006 Aug;36 Suppl 2:63-75 [16884399.001]
  • [Cites] Transplant Proc. 2000 May;32(3):556-7 [10812111.001]
  • [Cites] Transplant Proc. 2007 Apr;39(3):750-2 [17445589.001]
  • [Cites] Semin Dial. 2007 May-Jun;20(3):186-90 [17555478.001]
  • [Cites] Cochrane Database Syst Rev. 2007;(3):CD005015 [17636784.001]
  • [Cites] Clin J Am Soc Nephrol. 2006 Nov;1(6):1300-13 [17699362.001]
  • [Cites] Transplant Proc. 2008 Jan-Feb;40(1):160-6 [18261575.001]
  • [Cites] J Am Soc Nephrol. 2000 Jun;11(6):1093-9 [10820173.001]
  • [Cites] J Bone Miner Res. 2000 Sep;15(9):1818-24 [10977001.001]
  • [Cites] Am J Kidney Dis. 2000 Dec;36(6):1115-21 [11096034.001]
  • [Cites] J Bone Miner Res. 2001 Mar;16(3):565-71 [11277275.001]
  • [Cites] J Am Soc Nephrol. 2001 Jul;12(7):1530-7 [11423583.001]
  • [Cites] Transplant Proc. 2000 Nov;32(7):1876 [11119979.001]
  • [Cites] J Am Soc Nephrol. 2002 Jun;13(6):1608-14 [12039990.001]
  • [Cites] Nephrol Dial Transplant. 2002 Jul;17(7):1318-26 [12105258.001]
  • [Cites] Transplantation. 2003 Jan 15;75(1):49-54 [12544870.001]
  • [Cites] Kidney Int. 2003 May;63(5):1915-23 [12675872.001]
  • [Cites] J Am Soc Nephrol. 2003 Oct;14(10):2669-76 [14514747.001]
  • [Cites] J Am Soc Nephrol. 2003 Nov;14(11):2975-9 [14569109.001]
  • [Cites] Transplantation. 2003 Nov 27;76(10):1498-502 [14657693.001]
  • [Cites] Kidney Int. 2004 Feb;65(2):705-12 [14717945.001]
  • [Cites] Transplantation. 2004 May 27;77(10):1566-71 [15239623.001]
  • [Cites] Transplantation. 2004 Oct 27;78(8):1233-6 [15502727.001]
  • [Cites] N Engl J Med. 1991 Aug 22;325(8):544-50 [1857390.001]
  • [Cites] J Bone Miner Res. 1993 Sep;8(9):1137-48 [8237484.001]
  • [Cites] Kidney Int. 2005 May;67(5):2039-45 [15840055.001]
  • [Cites] Transplant Proc. 2006 Jan-Feb;38(1):165-7 [16504693.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):826-31 [16570003.001]
  • [Cites] Am J Transplant. 2008 Dec;8(12):2647-51 [18853956.001]
  • [Cites] Am J Kidney Dis. 2009 May;53(5):856-65 [19393473.001]
  • [Cites] Kidney Int Suppl. 2009 Aug;(113):S1-130 [19644521.001]
  • [Cites] J Bone Miner Res. 2006 Nov;21(11):1778-84 [17002574.001]
  • (PMID = 19965527.001).
  • [ISSN] 1555-905X
  • [Journal-full-title] Clinical journal of the American Society of Nephrology : CJASN
  • [ISO-abbreviation] Clin J Am Soc Nephrol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; FXC9231JVH / Calcitriol
  • [Other-IDs] NLM/ PMC2801646
  •  go-up   go-down


73. Cetingok M, Winsett RP, Russell CL, Hathaway DK: Relationships between sex, race, and social class and social support networks in kidney, liver, and pancreas transplant recipients. Prog Transplant; 2008 Jun;18(2):80-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationships between sex, race, and social class and social support networks in kidney, liver, and pancreas transplant recipients.
  • A total of 258 kidney, liver, and pancreas transplant recipients participated, 61% of whom were less than 50-years-old.
  • [MeSH-major] Kidney Transplantation / psychology. Liver Transplantation / psychology. Pancreas Transplantation / psychology. Social Class. Social Support


74. Koshinaga T, Hoshino M, Inoue M, Gotoh H, Sugito K, Ikeda T, Hagiwara N, Tomita R: Pancreatitis complicated with dilated choledochal remnant after congenital choledochal cyst excision. Pediatr Surg Int; 2005 Nov;21(11):936-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In these three cases, the choledochal remnant in the pancreas head was markedly dilated, probably because of an incomplete resection of the cyst at the primary operation, and an increase in intraluminal pressure of the pancreatic duct caused by a dynamic obstruction by a protein plug or a pancreatic calculus.
  • Complete cyst excision, including the choledochal wall in the pancreas, is therefore strongly recommended.
  • [MeSH-minor] Abdominal Pain / etiology. Adolescent. Adult. Dilatation, Pathologic. Female. Humans. Pancreas / diagnostic imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatitis.
  • MedlinePlus Health Information. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1979 Jun;14(3):315-20 [480094.001]
  • [Cites] Pancreas. 2003 May;26(4):405-7 [12717276.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1519-23 [11775184.001]
  • [Cites] Dig Dis Sci. 1989 Mar;34(3):367-71 [2920642.001]
  • [Cites] J Pediatr Surg. 1997 Jul;32(7):1097-102 [9247242.001]
  • [Cites] Hepatogastroenterology. 1999 May-Jun;46(27):1655-9 [10430315.001]
  • [Cites] J Pediatr Surg. 1980 Aug;15(4):437-42 [7411354.001]
  • [Cites] Scand J Gastroenterol. 2000 Dec;35(12 ):1324-9 [11199375.001]
  • [Cites] Am J Gastroenterol. 1986 May;81(5):378-84 [3706253.001]
  • [Cites] Pancreas. 2000 Oct;21(3):257-61 [11039469.001]
  • [Cites] Surg Clin North Am. 2001 Apr;81(2):379-90 [11392424.001]
  • [Cites] World J Surg. 1989 Mar-Apr;13(2):232-7; discussion 237 [2728469.001]
  • [Cites] J Pediatr Surg. 1986 Oct;21(10):873-6 [2431131.001]
  • [Cites] Br J Surg. 1997 Dec;84(12):1687-91 [9448616.001]
  • [Cites] J Am Coll Surg. 1996 Oct;183(4):317-21 [8843259.001]
  • (PMID = 16195912.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


75. Frossard JL, Quadri R, Hadengue A, Morel P, Pastor CM: Endothelial nitric oxide synthase regulation is altered in pancreas from cirrhotic rats. World J Gastroenterol; 2006 Jan 14;12(2):228-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endothelial nitric oxide synthase regulation is altered in pancreas from cirrhotic rats.
  • AIM: To determine whether biliary cirrhosis could induce pancreatic dysfunction such as modifications in endothelial nitric oxide synthase(eNOS) expression and whether the regulation of eNOS could be altered by the regulatory proteins caveolin and heat shock protein 90 (Hsp90), as well as by the modifications of calmodulin binding to eNOS.
  • METHODS: Immunoprecipitations and Western blotting analysis were performed in pancreas isolated from sham and cirrhotic rats.
  • RESULTS: Pancreatic injury was minor in cirrhotic rats but eNOS expression importantly decreased with the length (and the severity) of the disease.
  • CONCLUSION: In biliary cirrhosis, pancreatic injury is minor but the pancreatic nitric oxide (NO) production is significantly decreased by two mechanisms: a decreased expression of the enzyme and a decreased binding of calmodulin to eNOS.
  • [MeSH-major] Liver Cirrhosis, Biliary / enzymology. Nitric Oxide Synthase Type III / analysis. Pancreas / enzymology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Nov;117(5):1222-8 [10535886.001]
  • [Cites] Circ Res. 2002 May 3;90(8):838-41 [11988482.001]
  • [Cites] J Endocrinol. 1999 Oct;163(1):39-48 [10495405.001]
  • [Cites] Acta Physiol Scand. 2000 Jan;168(1):27-31 [10691776.001]
  • [Cites] Gastroenterology. 2000 Jul;119(1):201-10 [10889170.001]
  • [Cites] Pancreas. 2000 Oct;21(3):219-25 [11039464.001]
  • [Cites] Pancreas. 2000 Oct;21(3):248-56 [11039468.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jan;280(1):G68-74 [11123199.001]
  • [Cites] J Biol Chem. 2001 May 11;276(19):16587-91 [11340086.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2001 Jun;280(6):G1209-16 [11352814.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Aug;13(8):957-62 [11507362.001]
  • [Cites] Eur J Endocrinol. 2001 Sep;145(3):343-9 [11517016.001]
  • [Cites] Life Sci. 2001 Oct 19;69(22):2603-9 [11712664.001]
  • [Cites] Pharmacol Res. 2001 Dec;44(6):519-25 [11735360.001]
  • [Cites] Br J Pharmacol. 2002 Jan;135(2):489-95 [11815385.001]
  • [Cites] Digestion. 2002;65(2):118-26 [12021485.001]
  • [Cites] Gastroenterology. 2002 Jun;122(7):1869-77 [12055594.001]
  • [Cites] Nitric Oxide. 2002 Sep;7(2):91-102 [12223178.001]
  • [Cites] Pancreas. 2002 Oct;25(3):277-82 [12370539.001]
  • [Cites] Am J Physiol Regul Integr Comp Physiol. 2003 Jan;284(1):R1-12 [12482742.001]
  • [Cites] Int Immunopharmacol. 2002 Dec;2(13-14):1755-62 [12489789.001]
  • [Cites] Gastroenterology. 2003 Nov;125(5):1441-51 [14598260.001]
  • [Cites] Am J Physiol. 1997 Apr;272(4 Pt 1):G779-84 [9142908.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):606-14 [9247483.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):344-51 [9453496.001]
  • [Cites] Hepatology. 1998 Oct;28(4):926-31 [9755227.001]
  • [Cites] Life Sci. 1999;64(19):1753-9 [10353629.001]
  • [Cites] Clin Sci (Lond). 1999 Sep;97(3):313-8 [10464056.001]
  • [Cites] Eur J Pharmacol. 2001 Jul 6;423(2-3):185-93 [11448484.001]
  • [Cites] Nat Cell Biol. 1999 Oct;1(6):369-75 [10559965.001]
  • (PMID = 16482622.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cav1 protein, rat; 0 / Caveolin 1; 0 / HSP90 Heat-Shock Proteins; EC 1.14.13.39 / Nitric Oxide Synthase Type III
  • [Other-IDs] NLM/ PMC4066031
  •  go-up   go-down


76. Al-Masri M, Krishnamurthy M, Li J, Fellows GF, Dong HH, Goodyer CG, Wang R: Effect of forkhead box O1 (FOXO1) on beta cell development in the human fetal pancreas. Diabetologia; 2010 Apr;53(4):699-711
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of forkhead box O1 (FOXO1) on beta cell development in the human fetal pancreas.
  • However, the role of FOXO1 during pancreatic development remains largely unknown.
  • The present study aimed to characterise the expression of the FOXO1 transcription factor in the early to mid-gestation human fetal pancreas and to understand its role in islet cell development.
  • METHODS: Human (8-21 week fetal age) pancreases were examined using immunohistological, quantitative RT-PCR and western blotting.
  • RESULTS: Nuclear and cytoplasmic FOXO1 were widely produced during human fetal endocrine pancreatic development, co-localising in cells with the transcription factors pancreatic and duodenal homeobox 1 (PDX-1) and neurogenin 3 (NGN3) as well as cytokeratin 19 (CK19), insulin and glucagon.
  • CONCLUSIONS/INTERPRETATION: Our results indicate that FOXO1 may negatively regulate beta cell differentiation in the human fetal pancreas by controlling critical transcription factors, including NGN3 and NKX6-1.
  • [MeSH-major] Fetal Development / physiology. Forkhead Transcription Factors / genetics. Insulin-Secreting Cells / physiology. Pancreas / embryology

  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • Hazardous Substances Data Bank. GLUCAGON .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1649-54 [15668399.001]
  • [Cites] Dev Cell. 2003 Jan;4(1):119-29 [12530968.001]
  • [Cites] Mol Cell Biol. 2009 Aug;29(16):4417-30 [19506018.001]
  • [Cites] Diabetes. 2006 Jun;55(6):1581-91 [16731820.001]
  • [Cites] Nature. 2002 Sep 19;419(6904):316-21 [12239572.001]
  • [Cites] Int J Biochem Cell Biol. 2006;38(5-6):961-72 [16213778.001]
  • [Cites] J Clin Invest. 2008 Jun;118(6):2347-64 [18497885.001]
  • [Cites] Development. 1996 May;122(5):1409-16 [8625829.001]
  • [Cites] Nat Genet. 2002 Oct;32(2):245-53 [12219087.001]
  • [Cites] Clin Sci (Lond). 2005 Mar;108(3):195-204 [15631623.001]
  • [Cites] Diabetes Obes Metab. 2007 Nov;9 Suppl 2:140-6 [17919188.001]
  • [Cites] J Clin Invest. 2002 Dec;110(12 ):1839-47 [12488434.001]
  • [Cites] Sci STKE. 2003 Mar 04;2003(172):RE5 [12621150.001]
  • [Cites] Diabetes. 1996 Jun;45(6):711-7 [8635642.001]
  • [Cites] Nature. 1999 Aug 26;400(6747):877-81 [10476967.001]
  • [Cites] Diabetes. 2005 Jul;54(7):2080-9 [15983209.001]
  • [Cites] Diabetologia. 2008 Jul;51(7):1169-80 [18491072.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2975-80 [14978268.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90 [13679577.001]
  • [Cites] EMBO J. 1993 Nov;12(11):4251-9 [7901001.001]
  • [Cites] J Biol Chem. 2006 Jan 13;281(2):1091-8 [16282329.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):782-7 [10783894.001]
  • [Cites] N Engl J Med. 2000 Jul 27;343(4):230-8 [10911004.001]
  • [Cites] Cancer Cell. 2002 Jul;2(1):81-91 [12150827.001]
  • [Cites] J Pathol. 2009 Oct;219(2):182-92 [19544355.001]
  • [Cites] Development. 1995 Jan;121(1):11-8 [7867492.001]
  • [Cites] Diabetes. 2001 May;50(5):928-36 [11334435.001]
  • [Cites] J Clin Invest. 2007 Sep;117(9):2477-85 [17717603.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1798-807 [15618357.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14920-5 [14657333.001]
  • [Cites] Endocrinology. 2005 Mar;146(3):1025-34 [15604203.001]
  • [Cites] Diabetes. 2000 Feb;49(2):163-76 [10868931.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E475-83 [17519280.001]
  • [Cites] Endocr J. 2007 Aug;54(4):507-15 [17510498.001]
  • [Cites] J Cell Sci. 2007 Aug 1;120(Pt 15):2479-87 [17646672.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Cell Metab. 2005 Sep;2(3):153-63 [16154098.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2025-36 [11884591.001]
  • (PMID = 20033803.001).
  • [ISSN] 1432-0428
  • [Journal-full-title] Diabetologia
  • [ISO-abbreviation] Diabetologia
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Box Protein O1; 0 / Forkhead Transcription Factors; 0 / Insulin; 0 / RNA, Small Interfering; 0 / Transcription Factors; 9007-92-5 / Glucagon
  •  go-up   go-down


77. Smith GC, Trauer T, Kerr PG, Chadban SJ: Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey. Am J Kidney Dis; 2010 Apr;55(4):698-707
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective quality-of-life monitoring of simultaneous pancreas and kidney transplant recipients using the 36-item short form health survey.
  • BACKGROUND: Few risk factors for quality-of-life outcomes of simultaneous pancreas and kidney transplant recipients are known because of a paucity of data from prospective studies.
  • PREDICTORS: Demographic data; pretransplant Transplant Evaluation Rating Scale scores; current, past 12 months, and prior lifetime psychiatric disorder.
  • RESULTS: 37 simultaneous pancreas and kidney transplant recipients were assessed pretransplant and at 4 months posttransplant.
  • Current psychiatric disorder at pretransplant evaluation predicted higher PCS scores at 4 months (P = 0.002; regression coefficient, -15.42 [95% CI, -24.6 to -6.2]; effect size, 0.22) and 1 year (P = 0.002; regression coefficient, -17.3 [95% CI, -27.9 to -6.7]; effect size, 0.29).
  • Psychiatric disorder before the 12 months before the pretransplant evaluation predicted lower PCS scores at 4 months posttransplant (P < 0.001; regression coefficient, 14.98 [95% CI, 7.1-22.8]; effect size, 0.29).
  • Past psychiatric disorder is a risk factor.
  • [MeSH-major] Kidney Transplantation. Pancreas Transplantation. Quality of Life

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Pancreas Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20176426.001).
  • [ISSN] 1523-6838
  • [Journal-full-title] American journal of kidney diseases : the official journal of the National Kidney Foundation
  • [ISO-abbreviation] Am. J. Kidney Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Harries LW, Locke JM, Shields B, Hanley NA, Hanley KP, Steele A, Njølstad PR, Ellard S, Hattersley AT: The diabetic phenotype in HNF4A mutation carriers is moderated by the expression of HNF4A isoforms from the P1 promoter during fetal development. Diabetes; 2008 Jun;57(6):1745-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESEARCH DESIGN AND METHODS: We measured the expression of HNF4A isoforms in human adult tissues and gestationally staged fetal pancreas by isoform-specific real-time PCR.
  • The correlation between mutation position and age of diagnosis or age-related penetrance was assessed in a cohort of 190 patients with HNF4A mutations.
  • RESULTS: HNF4A was expressed exclusively from the P2 promoter in adult pancreas, but from 9 weeks until at least 26 weeks after conception, up to 23% of expression in fetal pancreas was of P1 origin.
  • In whole pancreas, HNF4A9 expression was greater than in islets isolated from the endocrine pancreas (relative level 22 vs. 7%).
  • CONCLUSIONS: We conclude that isoforms derived from the HNF4A P1 promoter are expressed in human fetal, but not adult, pancreas, and that their presence during pancreatic development may moderate the diabetic phenotype in individuals with mutations in the HNF4A gene.
  • [MeSH-minor] Adult. Aged. European Continental Ancestry Group. Female. Gene Expression Profiling. Humans. Kidney / physiology. Kidney / physiopathology. Male. Middle Aged. Pancreas / physiology. Pancreas / physiopathology. Polymerase Chain Reaction. Protein Isoforms / genetics

  • MedlinePlus Health Information. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Fetal Health and Development.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Diabetes. 2008 Jun;57(6):1461-2 [18511449.001]
  • (PMID = 18356407.001).
  • [ISSN] 1939-327X
  • [Journal-full-title] Diabetes
  • [ISO-abbreviation] Diabetes
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 081278/Z/06/Z
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HNF4A protein, human; 0 / Hepatocyte Nuclear Factor 4; 0 / Protein Isoforms
  •  go-up   go-down


79. Naugler C, Xu Z: Pancreatic adenocarcinoma metastatic to the pineal gland. J Clin Neurosci; 2008 Nov;15(11):1284-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic adenocarcinoma metastatic to the pineal gland.
  • Here we present the case of a 66-year-old female with autosomal dominant polycystic kidney and liver disease who was found at autopsy to have an unrecognized infiltrating ductal adenocarcinoma of the pancreas with metastases to the liver, lungs and pineal gland.
  • As far as we are aware, this is the first report of a metastasis of infiltrating ductal adenocarcinoma of the pancreas to the pineal gland.
  • [MeSH-major] Adenocarcinoma / pathology. Brain Neoplasms / secondary. Pancreatic Neoplasms / pathology. Pineal Gland. Pinealoma / secondary

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18829324.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


80. Atlas E, Nimri R, Miller S, Grunberg EA, Phillip M: MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes. Diabetes Care; 2010 May;33(5):1072-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MD-logic artificial pancreas system: a pilot study in adults with type 1 diabetes.
  • OBJECTIVE: Current state-of-the-art artificial pancreas systems are either based on traditional linear control theory or rely on mathematical models of glucose-insulin dynamics.
  • The aim of this study was to describe the principles and clinical performance of the novel MD-Logic Artificial Pancreas (MDLAP) System.
  • [MeSH-major] Diabetes Mellitus, Type 1 / therapy. Fuzzy Logic. Models, Biological. Pancreas, Artificial. Prosthesis Design

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 1.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Drug Deliv Rev. 2004 Feb 10;56(2):125-44 [14741112.001]
  • [Cites] Diabetes Technol Ther. 2004 Jun;6(3):307-18 [15198833.001]
  • [Cites] Physiol Meas. 2004 Aug;25(4):905-20 [15382830.001]
  • [Cites] Diabetes Technol Ther. 2009 Mar;11(3):187-94 [19191486.001]
  • [Cites] J Med Eng Technol. 2005 Mar-Apr;29(2):64-9 [15804854.001]
  • [Cites] Pediatr Diabetes. 2006 Aug;7 Suppl 4:45-9 [16774618.001]
  • [Cites] Med Eng Phys. 2007 Sep;29(7):824-7 [17052939.001]
  • [Cites] IEEE Trans Biomed Eng. 1999 Feb;46(2):148-57 [9932336.001]
  • (PMID = 20150292.001).
  • [ISSN] 1935-5548
  • [Journal-full-title] Diabetes care
  • [ISO-abbreviation] Diabetes Care
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00541515
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose
  • [Other-IDs] NLM/ PMC2858178
  •  go-up   go-down


81. Ramos O Jr, Leitão OR, Repka JC, Barros SG: [Experimental acute pancreatitis induced by L-arginine: a histological and biochemical evaluation]. Arq Gastroenterol; 2005 Jan-Mar;42(1):55-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Excessive doses of basic amino acids such as L-arginine are able to injure the pancreas of rats.
  • AIM: To describe and evaluate the biochemical and histological characteristics of acute pancreatitis in rats induced by L-arginine during the installation, development and repair stages of the pancreatic inflammatory process.
  • During those times, blood samples were collected for laboratory testing and samples from the pancreas were collected for an optical microscopy analysis.
  • In optical microscopy, after the injection of L-arginine, a pancreatic architecture histologically preserved was observed after 6 hours, evidencing an important interstitial edema in 24 hours.
  • The pancreatic structural reconstruction could be observed after 14 days.
  • Pancreatic histological changes were not found in the control group.
  • CONCLUSION: - Experimental acute pancreatitis induced by L-arginine leads to pancreatic necrosis showing self-limited evolution with pancreas regeneration in 2 weeks.

  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15976912.001).
  • [ISSN] 0004-2803
  • [Journal-full-title] Arquivos de gastroenterologia
  • [ISO-abbreviation] Arq Gastroenterol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Brazil
  • [Chemical-registry-number] 94ZLA3W45F / Arginine; EC 3.2.1.- / Amylases
  •  go-up   go-down


82. Choi CW, Kim GH, Kang DH, Kim HW, Kim DU, Heo J, Song GA, Park DY, Kim S: Associated factors for a hyperechogenic pancreas on endoscopic ultrasound. World J Gastroenterol; 2010 Sep 14;16(34):4329-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Associated factors for a hyperechogenic pancreas on endoscopic ultrasound.
  • AIM: To identify the associated risk factors for hyperechogenic pancreas (HP) which may be observed on endoscopic ultrasound (EUS) and to assess the relationship between HP and obesity.
  • Patients with a history of pancreatic disease or with hepatobiliary or advanced gastrointestinal cancer were excluded.
  • [MeSH-major] Endosonography. Pancreas / ultrasonography

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 2002 Jan 16;287(3):356-9 [11790215.001]
  • [Cites] Gut. 1984 Oct;25(10):1107-12 [6479687.001]
  • [Cites] Gerontology. 2000 Mar-Apr;46(2):93-6 [10671806.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1631-48 [12016428.001]
  • [Cites] J Clin Gastroenterol. 2002 May-Jun;34(5):560-8 [11960071.001]
  • [Cites] JAMA. 2003 May 21;289(19):2560-72 [12748199.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Aug;27(8):941-9 [12861235.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E906-16 [12959938.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 May;2(5):405-9 [15118979.001]
  • [Cites] Diabetes. 2004 Aug;53(8):2087-94 [15277390.001]
  • [Cites] Diabetes Care. 2004 Aug;27(8):2027-32 [15277435.001]
  • [Cites] J Clin Ultrasound. 1976 Jun;4(3):223-30 [818126.001]
  • [Cites] J Clin Ultrasound. 1977 Feb;5(1):25-9 [402391.001]
  • [Cites] Radiology. 1980 Nov;137(2):475-9 [7433680.001]
  • [Cites] Am J Gastroenterol. 1981 Aug;76(2):114-9 [7304546.001]
  • [Cites] Am J Clin Nutr. 1982 Jul;36(1):172-7 [7091027.001]
  • [Cites] AJR Am J Roentgenol. 1982 Dec;139(6):1095-8 [6983252.001]
  • [Cites] Endocr Rev. 2000 Dec;21(6):697-738 [11133069.001]
  • [Cites] Am J Clin Nutr. 1986 Dec;44(6):739-46 [3788827.001]
  • [Cites] Am J Clin Nutr. 1991 Jul;54(1):18-25 [2058582.001]
  • [Cites] Int J Obes. 1991 Sep;15 Suppl 2:53-7 [1794939.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1109-16 [7883959.001]
  • [Cites] Radiology. 1999 Apr;211(1):283-6 [10189485.001]
  • [Cites] Gastrointest Endosc. 2005 Mar;61(3):401-6 [15758911.001]
  • [Cites] Diabetes Care. 2006 Jan;29 Suppl 1:S43-8 [16373932.001]
  • [Cites] J Pediatr Gastroenterol Nutr. 2006 Jan;42(1):83-8 [16385259.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):462-9 [16799888.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Nov;91(11):4287-94 [16912127.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jun;23(6):900-7 [17995942.001]
  • [Cites] World J Gastroenterol. 2009 Apr 21;15(15):1869-75 [19370785.001]
  • [Cites] Pancreas. 2009 Aug;38(6):672-5 [19506531.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Oct;17(10):1098-105 [12201871.001]
  • [CommentIn] World J Gastroenterol. 2011 Apr 21;17(15):2061-2 [21528089.001]
  • (PMID = 20818817.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2937114
  •  go-up   go-down


83. Noguchi H: Pancreatic islet transplantation. World J Gastrointest Surg; 2009 Nov 30;1(1):16-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic islet transplantation.
  • Type 1 diabetes mellitus is an autoimmune disease, which results in the permanent destruction of β-cells of the pancreatic islets of Langerhans.
  • Clinical studies have shown that transplantation of pancreas or purified pancreatic islets can support glucose homeostasis in type 1 diabetic patients.
  • Islet transplantation carries the special advantages of being less invasive and resulting in fewer complications compared with the traditional pancreas or pancreas-kidney transplantation.
  • However, islet transplantation efforts have limitations including the short supply of donor pancreata, the paucity of experienced islet isolation teams, side effects of immunosuppressants and poor long-term results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160790.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999120
  • [Keywords] NOTNLM ; Islet isolation / Islet regeneration / Pancreatic islet transplantation / Pancreatic β-cells
  •  go-up   go-down


84. Komar G, Kauhanen S, Liukko K, Seppänen M, Kajander S, Ovaska J, Nuutila P, Minn H: Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res; 2009 Sep 1;15(17):5511-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness.
  • PURPOSE: To study blood flow (BF) and metabolism in normal pancreas and in different pancreatic lesions.
  • We then determined the effect of these biomarkers on outcome in patients with pancreatic cancer.
  • EXPERIMENTAL DESIGN: Oxygen-15-labeled water and fluorodeoxyglucose positron emission tomography/computed tomography scans were used in 26 patients with a suspicion of pancreatic cancer to measure pancreatic BF and metabolism.
  • Patients were divided into three groups: patients with a finding of normal pancreas (n = 7), benign lesions (n = 8), and malignant tumors (n = 11).
  • RESULTS: Patients with benign and malignant pancreatic tumors had decreased BF of the lesion by 48% and 60%, respectively, compared with patients with normal pancreatic tissue.
  • SUV(max) was 3-fold higher in malignant tumors compared with both benign lesions and normal pancreas (P < 0.05).
  • In contrast, the SUV(max) of patients with benign lesions and normal pancreas did not differ.
  • The SUV/BF ratio was significantly higher in malignant lesions than in benign lesions or in patients with normal pancreas (P < 0.05).
  • In patients with cancer, high SUV/BF ratio was a stronger predictor of poor survival compared with high metabolism or lower-than-normal pancreatic BF.
  • CONCLUSIONS: BF in pancreatic cancer is significantly reduced compared with the normal pancreas, which may in part explain the poor success of both radiotherapy and chemotherapy.
  • We suggest that the composite measurement of BF and metabolism in pancreatic cancer could serve as a novel tool in the planning of treatments targeting vasculature.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glucose / metabolism. Pancreatic Neoplasms / pathology. Regional Blood Flow
  • [MeSH-minor] Aged. Female. Fluorodeoxyglucose F18 / metabolism. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreas / blood supply. Pancreas / metabolism. Pancreas / pathology. Positron-Emission Tomography. Prognosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. GLUCOSE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2010 Jan 1;16(1):367; author reply 567 [20028758.001]
  • [CommentIn] Clin Cancer Res. 2009 Sep 1;15(17):5294-6 [19706819.001]
  • [CommentIn] Future Oncol. 2010 Jan;6(1):13-5 [20021204.001]
  • (PMID = 19706808.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0Z5B2CJX4D / Fluorodeoxyglucose F18; IY9XDZ35W2 / Glucose
  •  go-up   go-down


85. Brandhorst D, Iken M, Bretzel RG, Brandhorst H: Pancreas storage in oxygenated perfluorodecalin does not restore post-transplant function of isolated pig islets pre-damaged by warm ischemia. Xenotransplantation; 2006 Sep;13(5):465-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas storage in oxygenated perfluorodecalin does not restore post-transplant function of isolated pig islets pre-damaged by warm ischemia.
  • BACKGROUND: Cold storage in oxygenated perfluorodecalin (PFD) restores transplant function of ischemically damaged dog pancreata and reduces the impact of cold ischemia on recovery of isolated human islets.
  • Whether PFD storage can improve islet isolation from pancreata exposed to significant warm ischemia (WI) is unclear yet.
  • Resected pancreata were intraductally flushed with cold University of Wisconsin solution.
  • Subsequently, pancreata were processed immediately by digestion-filtration (group I: 0 min WI, n=6; II: 30 min WI, n=6) or first stored for 3 h in oxygenated PFD (III: 0 min WI+PFD, n=5; IV: 30 min WI+PFD, n=6).
  • RESULTS: Pancreata subjected to 30 min of WI yielded significantly less islets compared with the corresponding non-ischemic organs (I vs. II, P<0.01; III vs. IV, P<0.05).
  • PFD storage of ischemic organs partially restored ATP content (217+/-23 ng/1000 IEQ, II vs. IV, P<0.05) and glucose SI (1.60+/-0.09, II vs. IV, P<0.05) to a significant extent that reached the level of corresponding PFD-stored, non-ischemic pancreata (III vs. IV, NS).
  • The significantly reduced graft function of ischemic islets (I vs. II, III vs. IV, P<0.001) was not increased by pancreatic oxygenation (II vs. IV, NS).
  • CONCLUSIONS: The present study suggests that pancreas short-term storage in oxygenated PFD improves in vitro but not the in vivo function of ischemically damaged pig islets.
  • [MeSH-minor] Adenosine Triphosphate / metabolism. Animals. Cold Temperature. Hot Temperature. Insulin / metabolism. Pancreas / blood supply. Swine

  • MedlinePlus Health Information. consumer health - Islet Cell Transplantation.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16925671.001).
  • [ISSN] 0908-665X
  • [Journal-full-title] Xenotransplantation
  • [ISO-abbreviation] Xenotransplantation
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Insulin; 8L70Q75FXE / Adenosine Triphosphate
  •  go-up   go-down


86. Argyropoulou MI, Kiortsis DN, Astrakas L, Metafratzi Z, Chalissos N, Efremidis SC: Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study. Eur Radiol; 2007 Dec;17(12):3025-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver, bone marrow, pancreas and pituitary gland iron overload in young and adult thalassemic patients: a T2 relaxometry study.
  • T2 relaxation time (T2) of the liver, bone marrow, pancreas and pituitary gland was measured in a 1.5-Tesla magnetic resonance (MR) imager, using a multiecho spin-echo sequence (TR/TE 2,000/20, 40, 60, 80, 100, 120, 140, 160 ms).
  • The T2 of the pancreas was lower in adolescents (43.6 +/- 10.3 ms) than in adults (54.4 +/- 10.4 ms).
  • There was no significant correlation of the T2 among the liver, pancreas, pituitary gland and bone marrow.
  • There was no significant correlation between serum ferritin and T2 of the liver, pancreas and bone marrow.
  • After adolescence, age-related T2 changes are predominantly associated with pituitary siderosis and fatty degeneration of the pancreas.
  • [MeSH-major] Iron Overload / diagnosis. beta-Thalassemia / pathology
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / metabolism. Bone Marrow / pathology. Female. Humans. Liver / metabolism. Liver / pathology. Magnetic Resonance Imaging. Male. Pancreas / metabolism. Pancreas / pathology. Pituitary Gland / metabolism. Pituitary Gland / pathology. Statistics, Nonparametric

  • Genetic Alliance. consumer health - Iron Overload.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Best Pract Res Clin Haematol. 2002 Jun;15(2):329-68 [12401311.001]
  • [Cites] Pediatr Radiol. 1991;21(4):247-9 [1870916.001]
  • [Cites] Am J Pathol. 1978 Nov;93(2):295-309 [362939.001]
  • [Cites] Eur Radiol. 2007 Aug;17(8):2079-87 [17180327.001]
  • [Cites] Br J Radiol. 2001 May;74(881):407-10 [11388988.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2606-12 [11001918.001]
  • [Cites] AJR Am J Roentgenol. 2000 Dec;175(6):1567-9 [11090376.001]
  • [Cites] Neuroradiology. 2001 Dec;43(12):1056-8 [11792043.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 Mar-Apr;21(2):142-8 [10206461.001]
  • [Cites] J Endocrinol Invest. 2001 Oct;24(9):716-23 [11716158.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1135-46 [16162884.001]
  • [Cites] Biol Met. 1991;4(3):162-5 [1931435.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):187-92 [10397124.001]
  • [Cites] J Magn Reson Imaging. 2006 Feb;23(2):163-70 [16374880.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 May;28(5):311-5 [16772883.001]
  • [Cites] Lancet. 2004 Jan 31;363(9406):357-62 [15070565.001]
  • [Cites] NMR Biomed. 2004 Nov;17(7):427-32 [15526352.001]
  • [Cites] Magn Reson Imaging. 1995;13(7):967-77 [8583875.001]
  • [Cites] Diabetologia. 1987 Jan;30(1):5-12 [3552822.001]
  • [Cites] N Engl J Med. 1994 Sep 1;331(9):567-73 [8047080.001]
  • [Cites] Clin Endocrinol (Oxf). 1996 Apr;44(4):467-71 [8706315.001]
  • [Cites] Blood. 2005 Jan 15;105(2):855-61 [15256427.001]
  • [Cites] Mt Sinai J Med. 1993 Mar;60(2):95-103 [8469250.001]
  • [Cites] Cell. 2004 Apr 30;117(3):285-97 [15109490.001]
  • [Cites] Abdom Imaging. 2015 Oct;40(7):2777-82 [26023008.001]
  • [Cites] Pediatr Radiol. 2005 Nov;35(11):1045-55 [15928924.001]
  • [Cites] N Engl J Med. 1990 Sep 13;323(11):713-9 [2388669.001]
  • [Cites] Eur Radiol. 2003 Jan;13(1):12-6 [12541105.001]
  • [Cites] Eur Radiol. 2007 Jun;17(6):1535-43 [17149622.001]
  • [Cites] AJR Am J Roentgenol. 1997 May;168(5):1205-8 [9129412.001]
  • [Cites] N Engl J Med. 1999 Jul 8;341(2):99-109 [10395635.001]
  • [Cites] J Clin Pathol. 1983 May;36(5):539-45 [6302135.001]
  • [Cites] Prog Clin Biol Res. 1989;309:35-41 [2780748.001]
  • (PMID = 17549485.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Wente MN, Kleeff J, Esposito I, Hartel M, Müller MW, Fröhlich BE, Büchler MW, Friess H: Renal cancer cell metastasis into the pancreas: a single-center experience and overview of the literature. Pancreas; 2005 Apr;30(3):218-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Renal cancer cell metastasis into the pancreas: a single-center experience and overview of the literature.
  • OBJECTIVES: The pancreas is a rare target for metastasis from other primary cancers, but pancreatic metastasis play a role in the diagnostic workup of patients with pancreatic tumors, especially in patients with a history of renal cell carcinoma (RCC).
  • METHODS: Between October 2001 and June 2004 data from 601 patients undergoing pancreatic resection were entered prospectively in a database and were analyzed for metastasis into the pancreas from RCC.
  • RESULTS: Fifteen patients with metastasis to the pancreas from RCC were identified.
  • One patient showed metastatic disease at time of primary diagnosis.
  • In 8 patients, the pancreas was the only site of metastasis, whereas in 7 patients, other organs, such as the thyroid gland, the lung, or the liver, were targets of metastasis, either metachronous or simultaneous at the time of pancreatic metastasis.
  • The median interval between primary treatment of RCC and occurrence of pancreatic metastasis was 86 months (range, 0-258).
  • Most patients were asymptomatic and diagnosed during standard tumor follow-up.
  • CONCLUSION: Pancreatic metastasis from RCC is rare but can occur even more than 20 years after primary tumor manifestation.
  • Our results show that pancreatic resections for metastasis can be performed safely with a low rate of complications.
  • Patients with a history of RCC should undergo a long-term follow-up to detect and evaluate for pancreatic metastases as well for metastasis to other organ sites.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Databases, Factual. Kidney Neoplasms / pathology. Pancreatic Neoplasms / secondary


88. Capocasale E, Busi N, Mazzoni MP, Valle RD, Maggiore U, Bignardi L, Buzio C, Sianesi M: Simultaneous kidney-pancreas transplantation: the Parma Center experience. Acta Biomed; 2007 Aug;78(2):123-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous kidney-pancreas transplantation: the Parma Center experience.
  • Currently, it is demonstrated that simultaneous pancreas-kidney transplantation (SPK) shows beneficial effects on patient survival, on some diabetic degenerative complications and on the quality of life.
  • Aim of the work is to report our experience in pancreas transplantation.
  • Average pancreas cold ischemic time was 716 minutes (range 320-968).
  • No primary or delayed graft function was observed both for pancreas and kidney.
  • Pancreas and kidney graft survival rate was 76.5% and 94.1%, respectively.
  • Our experience, as reported in literature, confirm that a successful pancreas transplantation not only brings the recipient back to normal glycemic levels, but it also improves the patient's quality of life by stabilizing some of the secondary complications of diabetes.
  • [MeSH-major] Diabetes Mellitus, Type 1 / surgery. Kidney Transplantation. Pancreas Transplantation


89. Haider HH, Illanes H, Ciancio G, Miller J, Burke GW: Bezoar-related pancreatitis in enterically drained pancreas transplant. Transplant Proc; 2007 Jan-Feb;39(1):196-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bezoar-related pancreatitis in enterically drained pancreas transplant.
  • Simultaneous kidney and pancreas transplantation is currently the treatment of choice for type 1 diabetes mellitus with end-stage renal disease.
  • Causes of pancreatitis after pancreas transplantation with enteric drainage are not well documented in the literature.
  • We report a case of allograft pancreatitis from pancreatic duct outflow obstruction due to formation of a bezoar in a diverticulized transplant duodeno-jejunal anastomosis.
  • [MeSH-major] Bezoars. Diabetes Mellitus, Type 1 / surgery. Pancreas Transplantation / adverse effects. Pancreatitis / etiology


90. Gupta V, Singh V, Kalra N, Vaiphei K: Pancreas sparing resection for giant hamartoma of Brunner's glands. JOP; 2009;10(2):196-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreas sparing resection for giant hamartoma of Brunner's glands.
  • CONTEXT: Benign proliferative changes of the Brunner's glands account for about 10% of neoplasias of the duodenal bulb.
  • A pancreas-sparing duodenal resection was performed.
  • The diagnosis was established on histopathology.
  • A pancreas-sparing duodenal resection is one of the modalities of treating such lesions.
  • [MeSH-minor] Adult. Diagnosis, Differential. Duodenum / pathology. Duodenum / surgery. Female. Humans. Pancreaticoduodenectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287118.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


91. Kilbourn MR: Rat pancreas uptake of [11C]dihydrotetrabenazine stereoisomers. Nucl Med Biol; 2010 Nov;37(8):869-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rat pancreas uptake of [11C]dihydrotetrabenazine stereoisomers.
  • (+)-α-[(11)C]Dihydrotetrabenazine ((+)-[(11)C]DTBZ), a radioligand for the vesicular monoamine transporter type 2 (VMAT2), has been previously proposed as an in vivo marker of beta-cell degeneration in the pancreas.
  • The stereospecificity of uptake of [(11)C]DTBZ into rat pancreas was examined here using radiolabeled forms of the (+)- and (-)-isomers.
  • Pancreas localization of (+)-[(11)C]DTBZ could be partially blocked by prior administration of unlabeled (+)-DTBZ.
  • Pancreatic uptake of the (-)-isomer was unexpectedly high and could not be blocked by pretreatment with (+)-DTBZ, but could be significantly reduced by treatment with racemic tetrabenazine, an in vivo source of (-)-DTBZ.
  • These studies indicate that the inactive isomer of DTBZ does not provide a mechanism for defining the nonspecific binding of (+)-DTBZ in rat pancreas.
  • [MeSH-major] Pancreas / metabolism. Tetrabenazine / analogs & derivatives

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 21055616.001).
  • [ISSN] 1872-9614
  • [Journal-full-title] Nuclear medicine and biology
  • [ISO-abbreviation] Nucl. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 3466-75-9 / dihydrotetrabenazine; Z9O08YRN8O / Tetrabenazine
  •  go-up   go-down


92. Mohammed A, Janakiram NB, Li Q, Madka V, Ely M, Lightfoot S, Crawford H, Steele VE, Rao CV: The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila); 2010 Nov;3(11):1417-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.
  • Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy with a dismal prognosis.
  • Developing novel strategies to prevent or delay pancreatic cancer is currently of intense interest.
  • The chemopreventive efficacy of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, was evaluated against the progression of pancreatic intraepithelial neoplasms (PanIN) to PDAC in conditional LSL-Kras(G12D/+) transgenic mice.
  • At termination, pancreases were evaluated histopathologically for PanINs and PDAC, and various biomarkers were measured by immunohistochemistry, immunofluorescence, immunoblotting, and/or reverse transcription-PCR.
  • Furthermore, mice treated with 100 and 200 ppm of gefitinib exhibited 67.6% to 77.3% of the pancreas to be free from ductal lesions.
  • Also, gefitinib reduced EGFR, proliferating cell nuclear antigen, cyclin D1, C(2)GNT, RhoA, β-catenin, p38, phospho-extracellular signal-regulated kinase, caveolin-1, and mucin and increased cyclin B1 in the pancreatic lesions/PDAC.
  • In summary, these results show that gefitinib can prevent the progression of pancreatic cancer precursor lesions to PDAC in a preclinical model.
  • The present study highlights the promise of chemoprevention and the potential usefulness of EGFR inhibitors in individuals at high risk for pancreatic cancer.


93. Bergert H, Knoch KP, Meisterfeld R, Jäger M, Ouwendijk J, Kersting S, Saeger HD, Solimena M: Effect of oxygenated perfluorocarbons on isolated rat pancreatic islets in culture. Cell Transplant; 2005;14(7):441-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of oxygenated perfluorocarbons on isolated rat pancreatic islets in culture.
  • One impediment for a wider application of islet transplantation is the limited number of donor pancreata for islet isolation.
  • They serve also as oxygen "reservoirs" for harvested organs in pancreas organ transplantation.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Perflexane .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16285252.001).
  • [ISSN] 0963-6897
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorocarbons; 0 / Insulin; 0 / Oxygen Compounds; 9007-49-2 / DNA; FX3WJ41CMX / perflexane
  •  go-up